

516 Rec'd PCT/PTO

29 JUN 1999

PCT

FORM PTO-1390  
(REV 10-94)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)  
CONCERNING A FILING UNDER 35 U.S.C. 371

9555.94USWO

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

09/341009

INTERNATIONAL APPLICATION NO.

PCT/CA98/01010

INTERNATIONAL FILING DATE

October 29, 1998

PRIORITY DATE CLAIMED

October 31, 1997

## TITLE OF INVENTION

USE OF PROTEASOME INHIBITORS FOR TREATING CANCER, INFLAMMATION, AUTOIMMUNE DISEASE, GRAFT REJECTION AND SEPTIC SHOCK

## APPLICANT(S) FOR DO/EO/US

Jiangping WU; Xin WANG

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
  - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☒ has been transmitted by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
  - b. ☐ have been transmitted by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
  - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An unsigned oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

## Items 11. to 16. below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.  
☐ A SECOND or SUBSEQUENT preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☒ Other items or information: Copy of International Search Report; PTO Form 1449; 15 References

U.S. APPLICATION NO (If known, see 37 CFR 1.5) <div style="font-size: 2em; font-weight: bold; margin-top: 10px;">09/341009</div>	INTERNATIONAL APPLICATION NO PCT/CA98/01010	ATTORNEY'S DOCKET NUMBER 9555.94USWO
---	--	---

17. [X] The following fees are submitted:  <b>BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):</b> Search Report has been prepared by the EPO or JPO.....\$840.00  International preliminary examination fee paid to U.S. Patent and Trademark Office (37 CFR 1.492(a)(1)).....\$670.00  No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....\$760.00  Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(3)) paid to USPTO .....\$970.00  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....\$96.00	<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="text-align: center;"><b>CALCULATIONS</b></td> <td style="text-align: center;"><b>PTO USE ONLY</b></td> </tr> <tr><td colspan="2" style="height: 100px;"></td></tr> </table>	<b>CALCULATIONS</b>	<b>PTO USE ONLY</b>		
<b>CALCULATIONS</b>	<b>PTO USE ONLY</b>				

<b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>	<b>\$840.00</b>																									
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	\$																									
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 15%;">CLAIMS</th> <th style="width: 15%;">NUMBER FILED</th> <th style="width: 15%;">NUMBER EXTRA</th> <th style="width: 15%;">RATE</th> <th style="width: 15%;"></th> <th style="width: 15%;"></th> </tr> <tr> <td>Total claims</td> <td>20</td> <td>-20 = 0</td> <td>X \$18.00</td> <td>\$</td> <td></td> </tr> <tr> <td>Independent claims</td> <td>4</td> <td>-3 = 1</td> <td>X \$78.00</td> <td>\$78.00</td> <td></td> </tr> <tr> <td colspan="3">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$260.00</td> <td>\$</td> <td></td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			Total claims	20	-20 = 0	X \$18.00	\$		Independent claims	4	-3 = 1	X \$78.00	\$78.00		MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$			
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																							
Total claims	20	-20 = 0	X \$18.00	\$																						
Independent claims	4	-3 = 1	X \$78.00	\$78.00																						
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$																						
<b>TOTAL OF ABOVE CALCULATIONS =</b>	<b>\$918.00</b>																									
Reduction by 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).	\$																									
<b>SUBTOTAL =</b>	<b>\$918.00</b>																									
Processing fee of <b>\$130.00</b> for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).	+ \$																									
<b>TOTAL NATIONAL FEE =</b>	<b>\$918.00</b>																									
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property	+ \$																									
<b>TOTAL FEES ENCLOSED =</b>	<b>\$918.00</b>																									
	Amount to be: refunded	\$																								
	charged	\$																								

a. [X] Check(s) in the amount of \$918.00 to cover the above fees is enclosed.

b. [ ] Please charge my Deposit Account No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.

c. [X] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 13-2725.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

SEND ALL CORRESPONDENCE TO  
 Michael B. Lasky  
 MERCHANT & GOULD  
 3100 Norwest Center  
 90 South Seventh Street  
 Minneapolis, MN 55403

\_\_\_\_\_  
 SIGNATURE

\_\_\_\_\_  
 NAME

\_\_\_\_\_  
 29,555  
 REGISTRATION NUMBER

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION**

Docket No.  
9555.94-US-WO

Serjal No.

Filing Date

Patent No.

Issue Date

29-JUN-1999

Applicant/ **WU, Jiangping and WANG, Xin**  
Patentee:

Invention: **The Use of Proteasome Inhibitors for Treating Cancer, Inflammation, Autoimmune Disease,  
Graft Rejection and Septic Shock**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: Université de Montréal

ADDRESS OF ORGANIZATION: 2900 Boulevard Édouard-Montpetit
Montréal, Québec
CANADA
H3C 3J7

TYPE OF NONPROFIT ORGANIZATION:

- ☒ University or other Institute of Higher Education
- ☐ Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))
- ☐ Nonprofit Scientific or Educational under Statute of State of The United States of America  
Name of State: Citation of Statute:
- ☐ Would Qualify as Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)) if Located in The United States of America
- ☐ Would Qualify as Nonprofit Scientific or Educational under Statute of State of The United States of America if Located in The United States of America  
Name of State: Citation of Statute:

I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☐ the specification to be filed herewith.
- ☒ the application identified above.
- ☐ the patent identified above.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ no such person, concern or organization exists.  
☒ each such person, concern or organization is listed below.

FULL NAME Centre de recherche du Centre hospitalier de l'Université de Montréal  
 ADDRESS Campus Hôtel-Dieu, 3850, rue St-Urbain, Montréal, Québec, CANADA H2W 1T8

☐ Individual ☐ Small Business Concern ☒ Nonprofit Organization

FULL NAME \_\_\_\_\_  
 ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_  
 ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_  
 ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization


Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Jean Yvon Timothy  
 TITLE IN ORGANIZATION: Director, Office of Industrial Liaison  
 ADDRESS OF PERSON SIGNING: 2900 Boulevard Édouard-Montpetit, Montréal, Québec, CANADA H3C 3J7

SIGNATURE: \_\_\_\_\_



DATE: July 15, 1999

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION**

Docket No.  
9555.94-US-WO

Serial No.

Filing Date

Patent No.

Issue Date

29-JUN-1999

Applicant/ **WU, Jiangping and WANG, Xin**  
Patentee:

Invention: **The Use of Proteasome Inhibitors for Treating Cancer, Inflammation, Autoimmune Disease, Graft  
Rejection and Septic Shock**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: Centre de recherche du Centre Hospitalier de l'Université de Montréal

ADDRESS OF ORGANIZATION: Campus Hôtel-Dieu
3850, rue St-Urbain
Montréal, Québec
CANADA H2W 1T8
**TYPE OF NONPROFIT ORGANIZATION:**

- ☐ University or other Institute of Higher Education
- ☐ Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))
- ☐ Nonprofit Scientific or Educational under Statute of State of The United States of America  
Name of State: Citation of Statute:
- ☐ Would Qualify as Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)) if Located in The United States of America
- ☒ Would Qualify as Nonprofit Scientific or Educational under Statute of State of The United States of America if Located in The United States of America  
Name of State: Citation of Statute: **Non-profit research center**

I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☐ the specification to be filed herewith.
- ☒ the application identified above.
- ☐ the patent identified above.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ no such person, concern or organization exists.  
☒ each such person, concern or organization is listed below.

FULL NAME Université de Montréal

ADDRESS 2900 Boulevard Édouard-Montpetit, Montréal, Québec, CANADA H3C 3J7

☐ Individual ☐ Small Business Concern ☒ Nonprofit Organization

FULL NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

FULL NAME \_\_\_\_\_

ADDRESS \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: Pavel HAMET

TITLE IN ORGANIZATION: Directeur de la recherche

ADDRESS OF PERSON SIGNING: 3850, rue St-Urbain, Montréal, Québec, CANADA H2W 1T8

SIGNATURE: \_\_\_\_\_

DATE: \_\_\_\_\_

09/341009

80 Rec'd PCT/PTO 29 JUN 1999

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: WU, et al. Docket No.: 9555.94USWO  
Serial No.: Unknown Filed: Unknown  
Int'l Appln No.: PCT/CA98/01010 Int'l Filing Date: October 29, 1998  
Title: USE OF PROTEASOME INHIBITORS FOR TREATING CANCER,  
INFLAMMATION, AUTOIMMUNE DISEASE, GRAFT REJECTION  
AND SEPTIC SHOCK

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EL353244453US

Date of Deposit: June 29, 1999

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231.

By:   
Name: Tyrone Ross

PRELIMINARY AMENDMENT

Box PCT  
Assistant Commissioner for Patents  
Washington, D. C. 20231

Dear Sir:

In connection with the above-identified application filed herewith, please enter the following preliminary amendment:

IN THE SPECIFICATION

A courtesy copy of the PCT specification is enclosed herewith, but the World Intellectual Property Office (WIPO) copy should be relied upon if it is already in the U.S. Patent Office.

IN THE CLAIMS

In claim 5, line 1, delete "any one of claims 1 to 4" and insert --claim 1--.

655330-600450

In claim 6, line 1, delete "any one of claims 1 to 5" and insert --claim 1--.

In claim 7, line 1, delete "any one of claims 4 to 6" and insert --claim 4--.

In claim 8, line 1, delete "any one of claims 1 to 7" and insert --claim 1--.

In claim 13, line 1, delete "or 11".

In claim 20, line 1, delete "or 19".

#### REMARKS

The above preliminary amendment is made to remove multiple dependencies from claims 5-8, 13 and 20.

Applicant respectfully requests that the preliminary amendment described herein be entered into the record prior to calculation of the filing fee and prior to examination and consideration of the above-identified application.


If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicant's primary attorney-of record, Michael B. Lasky (Reg. No. 29,555), at (612) 336-4634.

Respectfully submitted,

MERCHANT, GOULD, SMITH, EDELL,  
WELTER, & SCHMIDT, P.A.  
3100 Norwest Center  
90 South Seventh Street  
Minneapolis, Minnesota 55402  
(612) 332-5300

Dated: June 29, 1999

By

  
\_\_\_\_\_  
Michael B. Lasky  
Reg. No. 29,555

MBL/sef

**TITLE OF THE INVENTION**

THE USE OF PROTEASOME INHIBITORS FOR  
TREATING CANCER, INFLAMMATION, AUTOIMMUNE DISEASE,  
GRAFT REJECTION AND SEPTIC SHOCK

5

**FIELD OF THE INVENTION**

The present invention relates to the use of proteasome  
inhibitors for targetting different cellular functions implicated in cancer,  
inflammation, autoimmune disease, graft rejection and septic shock.

10

**BACKGROUND OF THE INVENTION**

The proteasome is a large protease complex. It is the  
main nonlysosomal proteolytic system in the cell, and resides in the  
cytoplasm as well as in the nucleus (Jentsch et al., 1995, Cell 82:881).  
15 The proteasome possesses up to five different peptidase activities, in  
different catalytic domains (Ciechanover, 1994, Cell 79:13), and the best  
characterized ones are chymotrypsin-like, trypsin-like and  
peptidylglutamyl-peptide hydrolyzing (PGPH) activities (Orlowski et al.,  
1981, Biochem & Biophys. Res. Com. 101:814; Wilk et al., 1983, J.  
20 Neurochem 40:842). The proteasome is responsible for the degradation  
of 70-90% of cellular proteins (Rock et al., 1994, Cell 78:761). Yet its  
activity is well controlled and only those destined to be destroyed are  
timely digested by the proteasome. It therefore plays a critical role in  
irreversibly removing short-lived regulatory proteins, and other types of  
25 proteins. Indeed, the degradation of some important regulators of cell  
proliferation such as cyclin 2, cyclin 3, cyclin B, p53 and p27<sup>Kip1</sup> are  
mediated by the proteasome (Deshaies et al., 1995, EMBO J. 14:303;  
Yaglom et al., 1995, Mol. & Cell. Biol. 15:731; Salama et al., 1994, Mol.  
& Cell. Biol. 14:7953; Seufert et al., 1995, Nature 373:78; Scheffner et al.,

1993, Cell 75:495; Pagano et al., 1995, Science 269:682). The activities of several important regulators involved in cell activation are also controlled by the proteasome. For example, the transacting nuclear factor NF- $\kappa$ B becomes active after the enzymatic cleavage of its precursor by the proteasome (Palombella et al., 1994, Cell 78:773); I $\kappa$ B $\alpha$ , the inhibitor of NF- $\kappa$ B, and c-JUN protein are degraded via the proteasome pathway (Palombella et al., 1994, supra; Treier et al., 1994, Cell 78:787).

According to sedimentation rates, the proteasome could be purified as 26S and 20S complexes. The 20S proteasome is a cylindrical proteolytic core composed of multiple  $\alpha$  and  $\beta$  subunits. Each subunit is coded by a different gene in high eukaryotic cells and the total number of subunits varies among different species (Groettrup et al., 1996, Immunol. Today 17:429). *In vitro*, the purified 20S proteasomes can digest small peptides in an ATP-independent fashion, but they are inactive on intact folded proteins (Peters, 1994, Trends in Biochem. Sci. 19:377). The 20S proteasome can bind at its ends a 19S regulator and forms the 26S proteasome, which degrades ubiquitinated protein in an ATP-dependent fashion (Jentsch et al., 1995, supra). The 20S proteasome can also complex with an 11S activator called PA28 (Groettrup et al., 1996, supra). PA28 is a ring-like hexamer or heptamer composed of  $\alpha$  and  $\beta$  subunits (PA28 $\alpha$  and PA28 $\beta$ ), both of which are about 29KD in size (Realini et al., 1994, J. Biol. Chem. 269:20727; Ahn et al., 1995, FEBS Letters 366:37). It is not clear whether the 20S proteasome can associate both the 19S and 11S regulators at the same time.

There are two better characterized mechanisms regulating the protein degradation via the proteasome pathway. The first is that of the substrate selection. This process is controlled by a cascade of enzymes called the ubiquitin-activating enzyme (E1), the ubiquitin-

conjugating enzyme (E2) and the ubiquitin ligase (E3) (Jentsch et al., 1995, supra). In addition, the 19S regulator controls the entry of the ubiquitinated protein into the 20S catalytic core. The second mechanism is the activity of the 20S proteasome, which is enhanced by the 11S PA28 (Realini et al., 1994, supra). It is not clear whether and how the 11S PA28 exerts its effect on the 26S proteasome, since it and the 19S regulator do not seem to associate with the 20S at the same time. Moreover, whether the 20S complex exists in parallel to the 26S complex *in vivo* is still an open question. Nevertheless, it has been shown that overexpression of PA28 $\alpha$  could indeed augment significantly antigen processing by the proteasome in vivo (Groettrup et al., 1996, supra).

Certain peptide aldehydes such as N-acetyl-L-leuciny-L-leucinal-L-norleucinal (LLnL) and N-carbobenzyloxyl-L-leuciny-L-leuciny-L-norvalinal (MG115) are competitive inhibitors of chymotrypsin (Vinitsky et al., 1992, Biochem. 31:9421; Tsubuki et al., 1993, Biochem & Biophys. Res. Com. 196:1195). These agents could effectively block the chymotrypsin-like activity, and to a lesser extent, the trypsin-like and PGPH activities of the proteasome (Rock et al., 1994, supra). They have been employed to study the function of the proteasome in various cellular processes. A caveat of such studies is that these peptide aldehydes are not specific to the proteasome peptidases, and other cellular cysteine proteases such as calpain and cathepsin B (Rock et al., 1994, supra; Sasaki et al., 1990, J. Enzyme Inhib. 3:195) are also potently inhibited. This makes some interpretations less assuring.

Orlowski et al. in US patent 5,580,854 teach the use of peptidyl aldehydes and their analogues to inhibit proteolysis mediated by the multicatalytic proteinases complex (MPC) or proteasome. The use of such compounds is to inhibit intracellular protein degradation, mitosis and

proliferation of dividing cell population. This reference does not teach any apoptotic effect of proteasome inhibitors.

Palombella et al. in WO 95/25533 teach a method for reducing the cellular content and activity of NF-kB, a transcriptional factor playing a central role in immune and inflammatory response, by using proteasome inhibitors, peptidyl aldehydes.

Stein et al. in WO 95/24914 teach a method for reducing the rate of intracellular protein breakdown by inhibiting proteasome activity. The inhibitor MG 101 given as an example is shown to be an inhibitor of 26S proteasome. This inhibitory effect may result in inhibiting destruction of muscle proteins, antigen presentation and degradation of p53 .

Omura et al. have reported in 1991 the discovery of lactacystin (LAC) which could induce a neurite outgrowth (Omura et al., 1991, J. Antibiot. 44:113; Ibid., 44:117).

Fenteany et al. have subsequently found that LAC is a proteasome-specific protease inhibitor (Fenteany et al., 1995, Science 268:72). It inhibits the three major peptidase activities (i.e., chymotrypsin-like, trypsin-like, and PGPH activities) of the proteasome, and the inhibition of the first two is irreversible in in vitro assays. LAC does not affect other proteases such as calpain, cathepsin B, chymotrypsin, trypsin, and papain. Currently, LAC is the only proteasome-specific protease inhibitor available.

Schreiber in WO 96/32105 teaches lactacystin and various analogs to treat conditions that are mediated by the proteolytic function of the proteasome such as rapid elimination and post-translational processing of proteins involved in cellular regulation, intercellular communication and immune response, specifically antigen presentation.

Griscavage et al. (1996, PNAS 93:3308-3312) teach that proteasome activity is essential for the induction of nitric oxide synthase and that the proteasome peptidyl aldehyde inhibitors inhibit the induction of nitric oxide synthase. Nitric oxide production is implicated in initiating and exacerbating symptoms of acute and chronic inflammation (Lundberg et al., 1997, Nature Medicine 3:30-31). Thus the proteasome inhibitors, peptidyl aldehyde, by inhibiting nitric oxide induction have an anti-inflammatory activity. There is no teaching of reproducing the same effect using LAC which is more specific to proteasome than peptidyl aldehydes.

Cui et al. (1997, PNAS 94:7515-7523) had shown that T-cell hybridoma can be activated using dishes coated with anti-CD3. Once activated these cells die of apoptosis. It was demonstrated that lactacystin is an inhibitor of activation induced cell death (AICD) and, in these activated hybridoma T-cells, lactacystin must be administered within 2 hours of activation to efficiently block AICD. The same authors state that at higher doses LAC induces apoptosis in the artificial hybridoma T cells.

Grimm et al. (1996, EMBO 15:3835-3844) have shown that proteasome plays a role in thymocyte apoptosis and that peptidyl aldehyde derivatives that inhibit proteasome and LAC block apoptosis in some cases. In addition Grimm et al. (supra) reported that the LAC block of apoptosis was irreversible even when the drug was removed from the cell media. Imajoh-Ohmi et al. (Bioch. Biophys. Res. Com., 1995, 217:1070-1077), teach that lactacystin induces apoptosis in human monoblast U937 cells.

The involvement of mitochondria in the apoptotic process has been described by Kroemer et al. (Immunology Today, 1997, 18:44). Teachings relating to the mitochondrial control of apoptosis at the induction phase that appear to be essential are provided.

None of these references teach that proteasome inhibitors eliminate activated normal cells. There is no teachings in these references of the involvement of proteasome activity in mitochondrial function. In addition, these references do not describe in mammalian cells what proportion of the protease activity is derived from the proteasome and whether there are efficient and simple methods to screen for additional proteasome inhibitors.

LAC is the most specific inhibitor of proteasome available. It is mildly toxic and is unstable in aqueous solutions of high pH. LAC and some of its analogues binds directly to the proteasome and inhibits three peptidase activities of the proteasome. However, cellular events downstream of the proteasome are not totally clear. Knowledge of these down stream events related to proteasome activity will allow development of strategies and compounds capable of complementing, synergizing, or substituting the effect of proteasome inhibitors to maximize their effects and/or to minimize their side-effects.

It therefore appears that there is a need to investigate the role of proteasome and the effect of LAC or its analogues in the different cellular processes discussed above, and to develop an efficient screening method for searching additional proteasome inhibitors.

The present invention seeks to meet these and other needs.

The present description refers to a number of documents, the content of which is herein incorporated by reference.

#### **SUMMARY OF THE INVENTION**

Recent work of the Applicant has revealed that PA28  $\alpha$  and  $\beta$  expression is upregulated during T cell activation, and probably as a result, the *ex vivo* proteasome activity is fourfold higher in the activated

T cells than that in the resting T cells (Wang et al., 1997, Eur. J. Immunol. 27: November 1st, 1997, in press). Such an augmented activity likely reflects the increased need to destroy short-lived regulatory proteins and other types of proteins during T cell activation and proliferation.

5 Consequently, it is logical to hypothesize that blocking the proteasome activity will interfere with the activation and proliferation of T cells.

The invention demonstrates that proteasome is essential for progression of T cells from G<sub>0</sub> to S phase. Taking advantage of LAC's specificity and potency, this compound was used to investigate the role

10 of proteasomes in T lymphocyte activation and proliferation. It is demonstrated that the proteasome is essential for progression of T cells from the G<sub>0</sub> to S phase. Probably as a result of blockage of cycling, the activated but not resting T cells underwent apoptosis when treated with LAC. It is also shown that the proteasome controls the protein level of

15 p21<sup>Cip1</sup> and p27<sup>Kip1</sup> as well as the CDK2 activity in the G<sub>1</sub> phase, and such control mechanism might be essential in the cell cycle progression. LAC can effectively inhibit T cell proliferation even if added at the G<sub>1</sub>/S boundary. This knowledge is useful in administering LAC to reverse ongoing graft rejection during the rejection episode.

20 The present invention further relates to inducing apoptosis of activated T cells and T cell leukemia but not resting T cells with LAC or its analogues. Elimination of malignant cells by a proteasome inhibitor-induced apoptosis is useful in cancer therapy. In addition, normal T cells that become activated can be induced to undergo apoptosis with

25 a proteasome inhibitor thus eliminating antigen specific T cells. This is useful in ameliorating autoimmune diseases and graft rejection by generating antigen specific tolerance.

The invention further uses the knowledge of the proteasome involvement in protein degradation and in the steps for the

induction of nitric oxide synthase and the effect of LAC or its analogues on the expression of nitric oxide synthase and the production of nitric acid. This is useful in the prevention of septic shock and as an anti-inflammatory.

5                   The present invention also relates to the inhibition of proteasome activity by LAC or its analogues such that the inhibition interferes with cell-cell interaction during lymphocyte activation in mammals and the up-regulation of the adhesion molecule ICAM-1 is repressed. This is useful to control undesirable immune responses during  
10                   graft rejection, autoimmune diseases and inflammation.

                  The applicant is the first to show that the electron transport chain in mitochondria is dependent on the intact activity of the proteasome. The addition of proteasome - specific inhibitor such as LAC reduces the electron transport at the complex IV of the respiratory chain.  
15                   The addition of exogenous cytochrome C reverses this effect. The effect of LAC on mitochondria has potential applications for disorders that relate directly or indirectly to increased activity of mitochondrial function. As well, since proliferating cells have a higher energy requirement, inhibition of mitochondrial respiration could effectively curb the proliferation of  
20                   cancer cells and activated T cells by depriving the cells of energy, with minimal detriment to normal resting cells.

                  The applicant is further providing a method for screening proteasome inhibitors by assaying cellular proteinases activity with a tagged peptide substrate. It is understood that this assay protocol can be  
25                   used in a large through-put screening procedure and that any means of tagging peptide substrates specific to different protease activities of the proteasome and any means for detection known to a person skilled in the art, can be used and incorporated into the large through-put procedure.

All the elements comprising a method for screening proteasome inhibitors can be incorporated into a kit.

Therefore, in accordance with the present invention it is provided:

5

The use of a proteasome inhibitor to induce apoptosis in proliferating cells, wherein said proteasome inhibitor is lactacystin or an analogue thereof and said proliferating cells are cancerous cells and/or activated T cells, such that activated T cells are antigen induced. The above cells are stopped from progressing from G<sub>0</sub> to G<sub>1</sub>/M in a cell cycle as a consequence of proteasome inhibition. As well, CDK2 and the associated Cyclin E activities are substantially inhibited, whereby said cell cycle progression is substantially arrested. Additionally, CDK4 cell activity is not inhibited.

15

Any one of the use of the above stated provisioned uses of a proteasome inhibitor, wherein said proliferating cells are eliminated and cancer progression is arrested and, activated T cells are eliminated.

20

The use of a proteasome inhibitor to reverse graft rejection in a patient in need for such a treatment comprising the step of administering to said patient an apoptotic amount of a proteasome inhibitor when said patient T cells are activated wherein said patient is in need of said treatment when an ongoing allograft rejection occurs or at

25

least 24h after graft transplantation.

The use of a proteasome inhibitor in the making of a medicament to induce apoptosis in proliferating cells. The use of a proteasome inhibitor as defined in the above stated provisions, alone or

in combination with another medication, to eliminate or to reduce antigen-specific induced T or B cells, and achieve antigen-specific tolerant status or reduced responsiveness to an antigen in a patient which condition requires such treatment wherein said condition is selected from the group consisting of: autoimmune disease, graft rejection and inflammation.

A method for screening a compound for proteasome inhibition activity, which comprises: obtaining a mammalian cell lysate comprising proteasomes, a partially purified proteasomes preparation or a purified proteasomes preparation; tagging at least one peptide substrate specific to a known proteasome protease activity; combining said proteasomes and said at least one tagged peptide substrate; contacting the so combined proteasomes/tagged peptide substrate with said compound; said at least one tagged peptide substrate fails to release tag if said compound is a proteasome inhibitor, and detecting a decrease or absence of the released tag in the presence of said compound relating to the released tag in the absence of said compound as an indication of proteasome inhibition activity for said compound wherein said at least one tagged peptide substrate is a fluorogenic peptide and wherein said proteasome protease activity is trypsin-like chymotrypsin-like or peptidylglutamyl-peptide hydrolyzing activity.

The use of a proteasome inhibitor to disrupt mitochondrial function, wherein said inhibitor blocks electron transport in said mitochondria and, wherein said inhibitor blocks said electron transport at complex IV in said mitochondria such that mitochondrial function is disrupted, wherein disruption of mitochondrial function is corrected by cytochrome C. The use of the afore-mentioned provisions relating to mitochondrial function to treat a pathological condition wherein

high mitochondrial activity occurs, said pathological condition is selected from the group consisting of: cancer, inflammation, undesirable immune responses and hyperthyroidism.

5                               The use of a proteasome inhibitor to disrupt nitric oxide synthesis, wherein the proteasome inhibitor inhibits nitric oxide synthase gene expression.

10                               An apoptotic composition comprising a therapeutically effective amount of a proteasome inhibitor and a pharmaceutically acceptable carrier which may additionally comprise a therapeutically effective amount of an inhibitor to CDK4 activity and/or a therapeutically effective amount of an inhibitor to CDK2 activity and more particularly to Cyclin E activity, a therapeutically effective amount of an inhibitor which prevents p21<sup>Cip1</sup> upregulation blocks the degradation of p27<sup>Kip1</sup> and a  
15                               therapeutically effective amount of an inhibitor which prevents CD25 upregulation.

20                               The use of cyclosporin A, rapamycin or FK506 as a proteasome inhibitor.

25                               A composition for use in inhibiting graft rejection comprising a therapeutically effective amount of cyclosporin A, rapamycin or FK506 in combination with a therapeutically effective amount of a proteasome inhibitor and may be in combination with a therapeutically effective amount of an inhibitor of ICAM-1 expression.

A composition for use in inhibiting graft rejection comprising a therapeutically effective amount of an inhibitor which suppresses expression ICAM-1 in combination with a therapeutically effective amount of a proteasome inhibitor.

5

The use of a proteasome inhibitor to alleviate a disease or a disorder, wherein adhesion molecule ICAM-1 is upregulated and said disease or a disorder is graft rejection, autoimmune disease or inflammation.

10

The use of a proteasome inhibitor is to alleviate a disease or a disorder wherein at least one of CDK2, p21<sup>Cip1</sup>, CD25 is upregulated and/or p27<sup>kip1</sup> degraded, wherein said disease or disorder is graft rejection, autoimmune disease or cancer.

15

The use of a proteasome inhibitor to alleviate a disease or disorder, wherein nitric oxide synthase is upregulated and said disease or disorder is inflammation or septic shock.

20

The said proteasome inhibitor may be used alone or in combination with any drugs known in the art for use in treating cancer, inflammation, autoimmune disease, septic shock or inflammation.

25

The use of all the afore-mentioned provisions wherein said proteasome inhibitor is lactacystin or an analogue thereof.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

Having thus generally described the invention, reference will now be made to the accompanying drawings, showing by way of illustration a preferred embodiment thereof, and in which:

5                   **Figure 1** shows that LAC strongly inhibits T and B cell proliferation. Lymphocytes were stimulated with various mitogens as indicated, and LAC at different concentrations was added at the beginning of the cultures. The cells were pulsed with 3H-thymidine between 48h and 64h. Samples were in triplicates. All the experiments  
10 were performed at least three times and similar results were obtained. Representative results are shown.

A: Peripheral blood T cells stimulated with PHA (2 µg/ml).

B: Peripheral blood T cells stimulated with OKT3 (50ng/ml).

15 C: Peripheral blood T cells stimulated with anti-CD28 (50ng/ml) plus ionomycin (1 µg/ml).

D: Tonsillar B cells stimulated with SAC (1:15,000 dilution) and IL-2 (100 µ/ml).

20                   **Figure 2** shows that inhibition of the proteasome activity results in induction of apoptosis of activated normal cells and leukemic T cells but not resting normal T cells. Tonsillar T cells (A, B, and D) and Jurkat cells (C and E) were treated with LAC (10 µM for T cells and 6 µM for Jurkat cells). LAC was added at the beginning of the culture or 40h after T cell activation as indicated. The cells were harvested at the time points as shown. They were evaluated for their viability with trypan blue  
25 exclusion (A, B, and C), and for their mode of cell death according to DNA fragmentation (D and E).

**Figure 3** shows by electron microscopy that the proteasome inhibitor induced apoptosis in activated T cells and Jurkat cells.

A and B: Morphology of resting T cells treated with LAC. Tonsillar T cells were culture in the absence (A) or presence (B) of LAC (10mM) for 24h, and the cells were examined by EM.

5 C and D: Morphology of activated T cells treated with LAC. Tonsillar T cells were first activated with PHA (2 µg/ml) for 40h. The cells were then cultured in the absence (C) or presence (D) of LAC (10 µM) for additional 24h, and were examined with EM.

10 E and F: Morphology of Jurkat cell treated with LAC. Jurkat cells were cultured in the absence (E) or presence (F) of LAC (6 µM) for 24h and were evaluated with EM. Arrows indicate condensed nuclei.

**Figure 4** shows that the effect of LAC is rapid and reversible in cell culture.

15 A. The rapid effect of LAC Peripheral blood T cells were pretreated with 10 µM LAC in culture medium or in culture medium alone for 3h or 16h. The cells were then washed and recultured in the presence of 2 µg/ml PHA for 64h. The cells were pulsed with <sup>3</sup>H-thymidine for 16h before they were harvested at 64h. Samples were in triplicates.

20 B. The inhibitory effect of LAC on the proteasome activity was reversible in the cells Jurkat cells were pretreated with LAC (6 µM) in culture medium for 3h. The cells were washed and recultured at  $0.5 \times 10^6$  cells/ml for 0h, 5h or 21h. The cells were then harvested, washed and sonicated. The lysate protein (20 µg/sample) was assayed for its proteinase activity under a condition at which 90% of the activity was attributed to the proteasome. The samples were in duplicates. The result  
25 is expressed as relative fluorescence intensity at 440nm.

C. The activity of LAC in culture supernatants is short-lived LAC (6 µM) was added to Jurkat cell culture ( $0.5 \times 10^6$  cells/ml). The supernatants were harvested at 4h, 6h, 16h and 24h. These conditioned media were used

to culture fresh Jurkat cells for 3h. The cells were then harvested and assayed for the proteasome activity as described in Fig. 4B. Samples were in duplicates.

All the experiments were performed at least three times, and similar results were obtained. Representative data are shown.

**Figure 5** shows that LAC inhibits CD25 upregulation during T cell activation.

Peripheral blood T cells were stimulated with PHA (2  $\mu$ g/ml) for 48h in the presence or absence of LAC (10  $\mu$ M, added at the beginning of the culture). CD25 expression on T cells was evaluated by anti-CD25-PE/anti-CD3-FITC two-color flow cytometry. Similar results were obtained in two independent experiments, and a representative one is shown. The data are presented as two color histograms in forms of contours, as well as in an overlay histogram.

**Figure 6** shows the role of the proteasome in cell cycle progress.

A. LAC does not inhibit the progress from the  $G_2/M$  phase to the  $G_1$  phase in synchronized Jurkat cells Jurkat cells were synchronized at the  $G_2 /M$  phase by 16h nocodazole treatment. For the last 3h of the treatment, LAC (6  $\mu$ M) was added to the cultures destined to be treated by LAC later. The cells were then released by washing out nocodazole, and recultured in complete medium with or without 6  $\mu$ M LAC. The cells were sampled at 0h, 4h and 8h after the  $G_2/M$  release, stained with propidium iodide, and analyzed with flow cytometry.

B. LAC slows the cell cycle progress from the  $G_1/S$  boundary to the  $G_2/M$  phase in synchronized Jurkat cells Jurkat cells were synchronized at the  $G_1/S$  by isoleucine starvation followed by a hydroxyurea treatment. The synchronized cells were released by washing out hydroxyurea and were cultured in complete medium in the absence or presence of LAC

(6  $\mu$ M). The cells were sampled at 0h, 3h, 6h, 9h, 12h, 15h and 24h after the release, and were stained with propidium iodide and analyzed with flow cytometry.

C and D. LAC blocks the S phase entry of the mitogen-stimulated peripheral blood T cells. Peripheral blood T cells were stimulated with PHA (2  $\mu$ /ml) in the absence or presence of LAC (10  $\mu$ M, added at 0h, 16h, 24h, or 40h, as indicated in the bottom of the panels). For the flow cytometry analysis of the cell cycle progress, the cells were harvested at 0h, 16h, 40h and 64h as indicated on the top of the panels (Fig. 6C). For  $^3$ H-thymidine uptake, the triplicated cell samples were pulsed at 48h and harvested at 64h (Fig. 6D).

The experiments were performed three times, and similar results were obtained. Representative data are shown.

**Figure 7** shows the results of the kinase assays for the effect of LAC on CDK activity.

Tonsillar T cells were activated with PHA (2  $\mu$ g/ml) for a period as indicated in each graph. LAC (10  $\mu$ M) was added once at 0h. The cells were harvested at 16h, 24h, or 40h as indicated. An equal amount of lysate protein (40  $\mu$ /sample) was precipitated with rabbit anti-CDK4, anti-CDK2 or anti-Cyclin E antisera (2.5  $\mu$ g Ab/sample). The immune complexes were assayed for their kinase activities using histone H1 as a substrate. (A) CDK4 kinase activity. (B) CDK2 kinase activity. (C) Cyclin E-associated CDK activity. The membrane in (C) was subsequently hybridized with anti-Cyclin E (1  $\mu$ g/ml) followed by  $^{125}$ I-protein A for the evaluation of the protein level of Cyclin E.

All the experiments were performed three times, and similar results were obtained. Representative data are shown.

**Figure 8** shows the results of immunoblotting analysis of the effect of LAC on the protein levels of Cyclin E and Cyclin A.

Tonsillar T cells were stimulated with PHA (2  $\mu\text{g/ml}$ ) for 40h in the presence of hydroxyurea (1mM), and these cells were blocked at the  $G_1/S$  boundary ( $G_1$  block). The synchronization was released by washing out hydroxyurea, and the cells were recultured in medium containing 2  $\mu\text{g/ml}$  PHA in the absence or presence of LAC (10nM, added once at the time of the release). The cells were harvested at 6h and 22h post the  $G_1/S$  block. The cell lysates (40  $\mu\text{g/sample}$ ) were resolved in 10% SDS-PAGE, and transferred to PVDF membranes. The membranes were hybridized with rabbit-anti-Cyclin E or anticyclin A antisera followed by  $^{125}\text{I}$ -protein A. The Cyclin E level (Fig. 8A) and cyclin A level (Fig. 8B) of representative experiments are shown. Similar results were obtained in a total of three independent experiments.

**Figure 9** shows the results of immunoblotting analysis of the effect of LAC on the levels of CDK inhibitors  $p27^{\text{Kip1}}$  and  $p21^{\text{Cip1}}$ .

Tonsillar T cells were stimulated with PHA (2  $\mu\text{g/ml}$ ) for 16h, 40 or 64h in the absence or presence of LAC (10  $\mu\text{M}$ ). For the 16h and 40h culture, LAC was added once at 0h. For the 64h culture, LAC was added once at 40h. The cell lysates were resolved in 10% SDS-PAGE, and blotted onto PVDF membranes. The membranes were hybridized with rabbit anti- $p27^{\text{Kip1}}$  antisera (Fig. 9A) or with anti- $p21^{\text{Cip1}}$  antisera (Fig. 9B) followed by  $^{125}\text{I}$ -protein A. The experiments were performed three times, and similar results were obtained. Representative data is shown.

**Figure 10** shows human peripheral blood mononuclear cells that were cultured in medium (A), 2  $\mu\text{g/ml}$  PHA (B), or PHA plus 10  $\mu\text{M}$  lactacystin for 24h. Lactacystin could effectively block the aggregate formation.

**Figure 11** shows mouse lymph node cells that were cultured in medium (A), 2  $\mu\text{g/ml}$  Con A (B), or Con A plus 10  $\mu\text{M}$

lactacystin for 24h. Lactacystin could effectively block the aggregate formation.

**Figure 12** shows mouse lymph node cells from TCR transgenic mice named 2C that were cultured in medium (A), 2 µg/ml Con A (B), or Con A plus 10 µM lactacystin. After 24h and 48h, the cells were examined for ICAM-1 expression by flow cytometry, using FITC-anti-ICAM-1/ 1B2-PE. Monoclonal Ab 1B2 recognize a clonotypic determinant on the TCR of the transgenic T cells which are largely CD8 positive (>75%). Lactacystin could effectively block the upregulation of ICAM-1 on those CD8 positive T cells.

**Figure 13** shows mouse peritoneal exudate macrophages that were stimulated with 2 µg/ml LPS in the presence of lactacystin at different concentrations. Nitric oxide production by the macrophages was measured according to the nitrate concentrations in the supernatants.

**Figure 14** shows mouse peritoneal exudate macrophages that were stimulated with 2 µg/ml LPS in the presence or absence of lactacystin (10 µM). Nitric oxide synthase expression was measured with Northern blot analysis.

**Figure 15** shows that Lactacystin blocks electron transport downstream of Complex I. Respiration of Jurkat cells (JC) or rat kidney mitochondria (RKM) was measured by O<sub>2</sub> consumption using an oxygen electrode. The function of Complex I of digitonin (Dig)-permeated Jurkat cells was blocked by rotenone (Rot), and the respiration was resumed by adding succinate (Suc), which provides electrons to Complex II directly and thus bypasses Complex I. The maximal respiration was achieved by adding CCCP (carbonyl cyanide m-chlorophenylhydrazone), which uncouples the oxidation and phosphorylation. The respiration could be blocked by antimycin A (Ant), which inhibits Complex II. Curves 1 and

6 represent positive controls of rat kidney mitochondria. Curves 2 and 5 represent normals untreated Jurkat cells. Curves 3 and 4 represent Jurkat cells treated with lactacystin (6  $\mu$ M) for 2h and 4h, respectively.

**Figure 16** shows that Lactacystin blocks electron transport at Complex IV. Complex III in the respiration chain was blocked at Complex III antimycin (Ant), and the electron flow was resumed by adding ascorbate (Asc) and TMPD (tetramethyl-p-phenyl-enediamine). The maximal respiration was triggered by CCCP, and was totally inhibited by potassium cyanide (KCN).

**Figure 17** shows that Cytochrome completely corrects the defect at Complex IV caused by LAC. The assay system is identical to that described in Figure 16. Jurkat cells were treated with LAC for 4h (curve 3). The decoupling reagent used in this experiment to achieve maximal respiration is FCCP (carbonylcyanide-p-trifluoromethoxyphenylhydrazine).

**Figure 18** shows that RAPA, FK506, and CsA inhibit PA28 expression at the mRNA level. Tonsillar T cells (A) and B cells (B) were cultured in the presence of various reagents as indicated (PHA, 2  $\mu$ g/ml, RAPA, 10 nM; FK506, 10 nM, CsA, 1  $\mu$ M; SAC, 1:10 000 dilution; IL-2, 25 U/ml. After 6h, 20h or 40h, the cells were harvested and total RNA was analyzed by Northern blotting for PA28 $\beta$  expression. The PA28 $\beta$  message in T cells was also examined by Northern blotting using a similar condition as for PA28 $\beta$  (C). The experiments were repeated more than three times, and representative ones are shown.

**Figure 19** shows that RAPA inhibits PA28 $\beta$  and PA28 $\alpha$  protein in the activated T cells. (A) An analysis of PA28 $\beta$  protein by immunoblotting is shown. Tonsillar T cells were cultured with 2  $\mu$ g/ml PHA or PHA plus 50 nM RAPA for 24h. The cells were harvested and lysed. Forty micrograms of cleared lysate protein per sample was analyzed by

immunoblotting using rabbit anti-PA28 $\beta$  antiserum. (B) An analysis PA28 $\alpha$  and PA28 $\beta$  protein by confocal immunofluorescence microscopy. Tonsillar T cells were cultured with 2  $\mu$ g/ml PHA or PHA plus 50 nM RAPA for 24h. The cells were stained with antisera specific for PA28 $\alpha$  and PA28 $\beta$ . Thirteen cells were analyzed for PA28 $\alpha$  protein and twelve cells for PA28 $\beta$  protein in a blind fashion. The mean + SD of relative fluorescence intensity per whole cell is presented. Unpaired Student's *t*-test was employed for statistics. The difference between PHA-activated sample and PHA plus RAPA-treated samples was highly significant ( $p = 3.20 \times 10^{-9}$  for PA28 $\alpha$  and  $p = 5.99 \times 10^{-5}$  for PA28 $\beta$ ).

**Figure 20** shows that effect of RAPA on proteasome activity in human PBMC. Human PBMC were cultured in the absence or presence of 2  $\mu$ g/ml PHA or 10 nM RAPA for 16h-70h as indicated. The cells were then harvested, and the chymotrypsin-like activity of whole cells lysates was assayed in the absence or presence of 20  $\mu$ M proteasome inhibitor LAC. The data are presented as arbitrary units of fluorescence intensity per 20  $\mu$ g lysate protein. The experiments were repeated three times and a representative one is shown. Samples are in duplicate and the mean  $\pm$  SD is shown. (A) Total chymotrypsin-like activity in the lysate of PBMC. (B) Lactacystin-inhibitable chymotrypsin-like activity in the lysate of 70h PBMC. Nine micrograms of 20S proteasome were used as positive controls for the inhibitory effect of LAC at 10  $\mu$ M and 20  $\mu$ M. LAC was always added to the lysates during the proteinase assay 15 min before the addition of the substrate. The solid bars represent the activity in the presence of LAC. The net proteasome activities are calculated as the total activity minus the remaining activity after the LAC addition.

**Figure 21** shows the elimination of an alloantigen-specific response by a proteasome inhibitor lactacystin. The C57BL/6 spleen cells (H-2<sup>b</sup>) were stimulated with mitomycin c-treated BALB/c spleen cells (H-2<sup>d</sup>). On day 2 when most of the H-2<sup>d</sup>-specific cells were activated, the mixed lymphocyte culture (MLR) was treated with lactacystin (LAC, 8 $\mu$ M) for 3 h. After wash, the cells were put back in culture for additional 8 days, and then stimulated with either fresh BALB/c or C3H (H-2<sup>k</sup>) spleen cells. In MLR treated by LAC, the C57BL/6 cells failed to respond to the BALB/c cells, but respond well to third party C3H (H-2<sup>k</sup>) cells. The difference is more pronounced in day three of the culture.

**Figure 22** shows that the LAC-induced DNA fragmentation is inhibited by a broad spectrum caspase inhibitor zVAD.fmk. Jurkat cells were treated with LAC (6  $\mu$ M) in the absence or presence of different concentrations of zVAD.fms (0.4  $\mu$ M to 33.3  $\mu$ M) for 6 h. The cells were harvested and their DNA was analyzed by a DNA fragmentation assay according to DNA laddering.

**Figure 23** shows that preventing the degradation of a pro-apoptotic Bcl-2 family member Bik is a mechanism for the proteasome inhibitor-induced apoptosis. Jurkat cells were treated with lactacystin (6  $\mu$ M) for 5 h (lanes 2 and 4 of panel A), 4 h (lane 2 of panel B) or 7h (lane 3 of panel B), lane 1 in panels A and B is untreated control samples. The cells were separated into mitochondrial (mito in panel A and mitochondria in panel B) and cytosolic (cytosol in panel A) fractions, and the lysate of these two fractions analyzed by immunoblotting using goat anti- Bik, and rabbit anti-Bax, Bak and Bad Ab (all from Santa Cruz Biotech, Santa Cruz, CA) followed by enhanced chemiluminescence (ECL, kit from Amersham).

**Figure 24** shows that overexpression of an anti-apoptotic Bcl-2 family member Bcl-xL in a B cell line could protect the cells from apoptosis caused by proteasome inhibition. A human B cell line Namalwa was stably transfected with an anti-apoptotic Bcl-2 family member Bcl-xL, and its sensitivity to the proteasome inhibitor-induced apoptosis tested by the quantitative filter elution assay (Schmitt *et al.*, Exp. Cell Res. 240:107, 1998), which detects DNA fragmentation during apoptosis. The wild type Namalwa and transfected Namalwa cells overexpressing Bcl-xL were pulsed with  $^{14}\text{C}$ - thymidine for 24 h, and then treated with different concentrations of lactacystin (0.75  $\mu\text{M}$ , 1.5  $\mu\text{M}$ , 3  $\mu\text{M}$ , 6  $\mu\text{M}$  and 10  $\mu\text{M}$ ). The cells were harvested at different time intervals (24-96 h), and DNA fragmentation measured.

**Figure 25** shows that the wild type Namalwa cells have increased Bik level after treatment with lactacystin and that the Bcl-xL transfected Namalwa cells have overexpressed Bcl-xL. Jurkat cells, wild type Namalwa cells and Bcl-xL transfected Namalwa cells were treated with medium (lanes 1), staurosporine (0.3  $\mu\text{M}$ , lanes 2) and lactacystin (6  $\mu\text{M}$ , lanes 3) for 6 H. The proteins from the mitochondrial fraction of these cells were analyzed by immunoblotting and the amount of Bik, Bcl-xL, Bax, and Bak evaluated. The same membranes were used sequentially and probed with different antibodies against these factors. A nonspecific band recognized by a monoclonal antibody against cytochrome oxygenase (COX) was used as control for even sample loading in the lanes.

Other objects, advantages and features of the present invention will become more apparent upon reading of the following non-restrictive description of preferred embodiments with reference to the accompanying drawings which are exemplary and should not be interpreted as limiting the scope of the present invention.

## **DESCRIPTION OF THE PREFERRED EMBODIMENT**

The present invention relates to proteasome activities in cellular processes and any inhibitors of proteasome activities.

### **5     Proteasome Activity is Obligatory for Activation and Proliferation of T and B Cells**

10     The role of proteasome in T cell activation and proliferation was first examined in PBMC, using the proteasome-specific inhibitor LAC. The PBMC were activated with various stimulants. LAC was added to the cells in the beginning of the culture (0h) along with the stimulants. <sup>3</sup>H-thymidine uptake between 48h and 64h of 64h cultures was used as a parameter for cell proliferation. As shown in Fig. 1, LAC strongly and dose-dependently inhibited the T cell proliferation induced by a T cell mitogen PHA (Fig. 1A), by crosslinking TCR with anti-CD3e (Fig. 1B), or by Ca<sup>++</sup> ionophore plus cross-linking of the T cell co-stimulating molecule CD28 (Fig. 1C). The T cell-independent B cell proliferation induced with SAC plus IL-2 in tonsillar B cells was also potently inhibited by LAC (Fig. 1D). In all the four systems employed, LAC at 5 μM could exert near-to-maximal inhibition. The results suggest that LAC's effect is not lymphocyte type(T or B cells)-specific nor stimulant-specific. Rather, it likely affects certain downstream events governing a more general process(es) in lymphocyte activation and proliferation.

### **LAC Causes Apoptosis in Activated but not Resting T Cells**

25     In one embodiment of the present invention a compound is provided that induces activated and leukemic T cells to undergo apoptosis.

Since LAC has been reported to induce apoptosis in U937 cells (Chen et al., 1996, J. Immunol. 157:4297), it is crucial to

examine whether the LAC-induced inhibition of cell proliferation is due cell death, be it apoptosis or necrosis.

The viability of T cells and Jurkat cells after LAC-treatment was first evaluated with trypan blue exclusion. Resting T cells (T cells in medium) or PHA-stimulated T cells were cultured with 10  $\mu$ M LAC (LAC added at the beginning of the culture). As shown in Figure 2A, after 16h culture, the viability of the cells only had minor decreases (< 12%) in LAC-treated cells compared with those without LAC (97% vs 92% for cells in medium, and 94% vs 83% for cells with PHA). After a prolonged culture for 64h, the decreases were more prominent although were still less than 27%(97% vs 79% for cells in medium, and 90% vs 63% for cells with PHA).

There was a tendency that the activated T cells were more susceptible to LAC than the resting T cells. This became more evident when LAC was added to T cells 40h after the PHA activation (Figure 2B). The viability of the activated T cells dropped from 94% to 46% after additional 24h culture, although 9h culture did not change the viability significantly according to trypan blue exclusion. On the other hand, the viability of the resting T cells in medium had only a small decrease (from 98% of the control to 87% of the LAC-treated) after 24h of LAC presence.

Why did LAC added at 0h along with PHA cause less cell death compared with LAC added at 40h post PHA stimulation (Figure 2A vs 2B)? It will be demonstrated that LAC is rapidly degraded in the cell culture. After 24h in culture medium, LAC lost its activity, and at 40h when the T cells were fully activated and become more susceptible, there was no biologically active LAC in the culture. This could explain the observed difference in terms of viability between the 0h and 40h addition of LAC to the PHA-activated T cells.

The effect of LAC on Jurkat cells was quite similar to that on the activated T cells. Less than 8h exposure to 6  $\mu$ M LAC did not induce apparent Jurkat cell death, while about 60% of the Jurkat cells were trypan blue positive after 24h culture with LAC (Fig. 2C).

5 We next employed DNA laddering to study the mode of cell death caused by LAC, and the result of this experiment also reflected the degree of cell death after different treatments. As shown in Fig. 2D, resting T cells treated with 10  $\mu$ M LAC for 24h had no apparent DNA breakdown (lanes 1 and 2). This correlated to the good cell viability as shown in Fig. 2B. On the other hand, clear DNA ladders could be observed from activated T cells (40h post PHA-stimulation) treated with LAC for additional 9h (lanes 3 and 4). After 24h of LAC treatment, the ladders became less discrete, and this probably reflected further DNA breakdown. For Jurkat cells, DNA fragmentation could be detected as early as 6h after the LAC treatment, and after 16h, the fragmentation became more prominent (Figure 2E).

Electron microscopy was also employed to examine the mode of cell death induced by LAC. The resting T cells (cells cultured in medium, figure 3A), activated T cells (40h after PHA activation, Figure 3C), and Jurkat cells (Figure 3E) were all healthy looking. Occasional condensed nuclei were observed in medium cultured T cells (Figure 3A) and this is not unusual. The resting T cells treated with LAC (10  $\mu$ M) for 24h were still healthy (Figure 3B). However, nuclear condensation, which is a hallmark of apoptosis, were frequently observed in activated T cells and Jurkat cells after they were exposed to LAC (10  $\mu$ M and 6  $\mu$ M, respectively) for 24h (Figures 3D and F).

Following conclusions are drawn from the results of this section. 1) Resting T cells or T cells in their early activation phase (less than 24h after PHA-stimulation) are not sensitive to LAC in terms of cell

viability. Consequently, there are still a significant percentage of live cells after 64h culture should LAC be added once at the beginning. 2) Less than 8-9h of LAC treatment does not affect significantly viability of activated T cells (40h post PHA activation) or Jurkat cells, according to trypan blue exclusion. 3) Prolonged treatment (24h) of the activated T cells or Jurkat cells with LAC causes cell death in the form of apoptosis, although signs of apoptosis could be detected as early as 9h in T cells and 6h in Jurkat cells after the LAC treatment.

The data in this section further infer following notions. 1) LAC's differential effect on the viability of resting versus cycling cells suggests that it is not simply nonspecific cytotoxicity, but relates to the status of the cell cycle. 2) The cell death without doubt contributes to but cannot solely account for the observed inhibition of proliferation by LAC, since there are still significant percentage ( about 60%) of live cells at the end of the culture according to trypan blue exclusion. Moreover, we will elaborate later that the cell death is a consequence of blockage of cell cycle progress. 3) Admittedly the trypan blue negative cells includes some early apoptotic cells, as evidenced by the fact that DNA laddering could be detected in a largely trypan blue negative population. However, it does not necessarily mean that the whole population is dead. We will later demonstrate that most Jurkat cells treated with LAC for 6h to 8h could still progress normally in cell cycle, in spite that a certain degree of apoptosis could be detected in these cells. 4) LAC could be used to study the role of proteasomes in lymphocyte activation and proliferation, as long as the compound is applied only once in the beginning of activation of the resting T cells and the experimentation is carried out in 24h-40h, or LAC is present for less than 8h in the case of cycling cells, since such treatments do not drastically affect the viability of the cells.

A specific embodiment of this invention is the ability of LAC to induce apoptosis mostly in activated and proliferating cells and not in normal resting cells. This has value in eliminating cancerous cells and antigen-specific T cells. The elimination of the latter will create a specific immune tolerance to alloantigens in transplantation, and to selfantigens in autoimmune diseases.

### **The Effect of LAC is Rapid and Reversible**

We next investigated how fast and how long LAC could exert its effects on the lymphocytes, since this information is necessary to assess the requirement of the proteasome activity for events related to cell activation and proliferation. PBMC were pretreated with LAC (10  $\mu$ M) or medium for a period as indicated in Fig. 4A. The cells were then washed and recultured in the presence of PHA. The thymidine uptake was measured 3 days later. It was clearly demonstrated that 3h preincubation with LAC was sufficient to cause significant inhibition on the subsequent mitogen-stimulated proliferation in T cells, although 16h preincubation with LAC was more effective. This result indicates that LAC can enter the cells rapidly within 3h.

We used Jurkat cells that have high constitutive proteasome activity to evaluate the duration of LAC's effect once the drug entered the cells. Jurkat cells were treated with LAC (6  $\mu$ M) for 3h, which was sufficiently long for the compound to enter the cells as shown above. The cells were then thoroughly washed and recultured, and they were harvested at 0h, 5h and 21h after the wash, and the proteasome activity in the cell lysates was measured using a chromogenic chymotrypsin substrate. We have previously established that the proteinase activity measured by this assay was predominantly (more than 90%) derived from the proteasome (Wang et al., 1997, Eur. J. Immunol., supra). As shown

in Fig. 4B, the proteasome activity in Jurkat cells was almost completely inhibited by 3h preincubation with LAC at 6  $\mu$ M. Five hours after the LAC was washed out, the proteasome activity in the cells was still significantly inhibited but the inhibition was reduced compared with that at 0h. By 21h, the proteasome activity returned to a near-normal level. It is to be noted that the short 3h treatment with LAC did not affect the viability of the Jurkat cells, and this is also reflected by the normal proteasome activity of the treated cells at 21h. The result shows that LAC is not stable and loses its activity within 21h in the cells.

We also investigated whether LAC was stable in the culture supernatant. LAC (6  $\mu$ M) was added to Jurkat cells culture for 4h, 6h, 16h or 24h. The conditioned medium was harvested and used to treat fresh Jurkat cells for 3h, and then the proteasome activity in the lysates of the fresh Jurkat cells was assayed. As shown in Fig. 4C, 4h to 24h conditioned media without LAC did not affect the proteasome activity of the fresh Jurkat cells. The media conditioned with LAC up to 6h could still actively inhibit the enzymatic activity, but after 16h, the LAC-conditioned media lost their inhibitory effect. The loss of LAC activity in the 16h and 24h conditioned medium is unlikely due to trapping of LAC by proteasomes released by dead Jurkat cells, because LAC could rapidly enter the live cells and the equilibrium of the LAC concentration between both sides of the cytoplasmic membrane should be established very fast. Thus, the proteasomes whether released or not should not make a difference in terms of trapping LAC. Besides, we have also noticed that LAC kept in cell free culture medium at 4°C would lose its activity within 24h (data not shown). These results indicate that LAC is not only unstable within the cells, but is also unstable in the supernatant.

LAC's capability to enter the cells to inhibit the proteasome activity rapidly (less than 3h), and its short active duration

within the cell and in the culture media (about 16h) makes the compound a very useful reagent to evaluate the requirement of the proteasome activity in various events during cell activation and proliferation, since we could pinpoint the period when the proteasome activity is critical.

5                   It is an embodiment of this invention, the use of LAC can be regulated in a time course sequence to be most effective at the period when proteasome activity is critical to maximise the effect of LAC on cells.

### **Proteasome Activity is Required for IL-2R $\alpha$ Upregulation**

10                   In the four systems of T and B cell activation and proliferation studied in the first section, the growth promoting activity of IL-2 is indirectly (for stimulation by PHA, anti-CD3, and anti-CD28 plus ionomycin), or directly (for SAC plus IL-2) involved. We then investigated the role of proteasome in IL-2R $\alpha$  expression and IL-2 production. As  
15 shown in Fig. 5, CD25 was upregulated in CD3<sup>+</sup> T cells 40h after stimulation with PHA. When LAC (10  $\mu$ M) was added in the beginning of the culture, the upregulation was significantly inhibited. On the other hand, IL-2 production by PBMC 2 to 4 days after PHA stimulation in the absence or presence of LAC (10  $\mu$ M, added at the beginning of the  
20 culture) was also examined, but no consistent difference was found (data not shown). Under the experimental condition used, the viability of the LAC-treated cell was reasonable (>80% at 40h) as described in the previous section as LAC was added only once initially. Moreover, no consistent change of IL-2 production in LAC-treated cells was a functional  
25 indication that the cell viability was reasonable and is not of a concern in interpreting the data. The results from this section indicate that IL-2R $\alpha$  upregulation but not IL-2 production is proteasome-dependent, and the suppressed IL-2R $\alpha$  expression likely contributes to LAC's inhibitory effect on T cells activation and proliferation.

### The Proteasome Activity is Critically Required Between G<sub>0</sub> and G<sub>1</sub>/S Boundary in T Cells

Like normal T cells, the proliferation of Jurkat cells was also potentially inhibited by LAC (data not shown). We used synchronized Jurkat cells to identify the LAC-sensitive phase(s) of the cell cycle. Jurkat cells were first synchronized at the G<sub>2</sub>/M boundary by nocodazole (Fig. 6A). The cells were released from the blockage by washing out nocodazole. In the control sample, more than half the cells traversed through the M phase and arrived at the G<sub>1</sub> phase within 4h. In the test sample, LAC (6  $\mu$ M) was added to the culture 3h before the release, so the compound could have enough time to enter the cells. LAC was also added to the culture after the release. However, the Jurkat treated with LAC traversed through the M phase to the G<sub>1</sub> phase at a similar pace as the control cells. Since the total duration of the assay was around 7h (3h preincubation plus 4h after the release), LAC was certainly active during this period. The fact that most of synchronized Jurkat cells could traverse through G<sub>2</sub>/M to G<sub>1</sub> in the presence of LAC for 7h again suggests that the viability of the cells thus treated is not a matter of concern. This result shows that the G<sub>2</sub> to G<sub>1</sub> progression is not proteasome-dependent.

We next studied requirement of the proteasome activity for the progression from the G<sub>1</sub>/S boundary to the G<sub>2</sub>/M phase. The Jurkat cells were synchronized at the G<sub>1</sub>/S boundary by HU blockage. The cells were then released by washing out HU. Within 9-12h, the majority of the cells progressed to the S and G<sub>2</sub>/M phase (Fig. 6B). When LAC was added to the culture immediately after the release, it slowed but did not block the cell cycle progression from the G<sub>1</sub>/S boundary to the G<sub>2</sub>/M phase, as evidenced by the histograms at 6h and 9h post the release. It is to be noted that although the percentage of cells in the S/G<sub>2</sub>/M phase in the LAC-treated sample was similar to that of controls (the inset table

of Figure 6B), the peak of fluorescence was lagged behind (histogram array). Beyond 9h, the cells gradually lost their synchronization, the viability of the cells started to decline and LAC gradually lost its activity, so the data became difficult to interpret. The result from this part suggests that the proteasome activity is required for optimal progression from the  $G_1/S$  boundary to the  $G_2/M$  phase, because the progression could still proceed albeit at a slower pace when the proteasome activity is inhibited. The result also implies that the absolutely proteasome-dependent window during the cell cycle, as evidenced by the near-total inhibition of S phase entry in LAC-treated mitogen-stimulated lymphocytes according to the proliferation data, must be in the  $G_1$  phase before the target point of HU, which inhibits ribonucleotide reductase in the  $G_1/S$  boundary (Brown et al., 1996, Cell 86:517).

The cycling Jurkat cells are obviously not the best model to study the events in the  $G_1$  phase since the  $G_1/M$  synchronization become desynchronized by the time the cells re-enter the S phase, and there is no appropriate method to synchronize the Jurkat cells at the early  $G_1$  phase. We therefore decided to use mitogen-stimulated normal T cells to study the role of the proteasome in the  $G_1$  phase.

T cells from PBMC were at  $G_0$  when isolated. After 16h stimulation with PHA, they remained before the S phase (Fig. 6C). At 40h, about 20% of the cells were in the S and  $G_2/M$  phases. The peak of  $^3H$ -thymidine uptake according to a 16h pulse was between 48h and 64h (data not shown), although at 64h, the cells in the S and  $G_2/M$  phases were still about 20% (Fig. 6C). The lack of an increase in percentage of cells in the S and  $G_2/M$  phases at 64h compared with that at 40h was likely due to the exit of the cells from the S and  $G_2/M$  phase. It is to be noted that the cycling T cells in this system never reaches 100%, because about 15% of the cells were non T cells, and an additional 20%

were non responsive T cells. Taken the cell proliferation and cell cycle analysis together, the  $G_1/S$  boundary of the cycling T cells should be between about 35h and 48h after the PHA stimulation. The boundary was broad because the synchronization was not ideal.

5                    In this model, the role of the proteasome in the S phase entry was examined. As shown in Fig. 6C, LAC added once at 16h could totally block the S phase entry when examined at 40h. We have noticed that when the cell viability was evaluated at 40h, there was an increase of cell death comparing the 16h addition of LAC with the 0h addition (about 25% vs about 17%, data not shown). The increased cell death was also reflected in the cells with  $< 2N$  DNA in the 40h histogram. However, such a viability was still reasonable and would not invalidate our conclusion. According to  $^3H$ -thymidine uptake, LAC was strongly inhibitory even added as late as 40h (Fig. 6D). However, no difference on the percentage of the population in the S and  $G_2/M$  phase was observed at 15 64h whether or not LAC was added at 40h according to flow cytometry (Fig. 6C). The discrepancy could be explained by the fact that the 20% cells were already in the S and  $G_2/M$  phases at 40h when LAC was added. LAC prevented additional cells from entering into the S phase, therefore the lack  $^3H$ -thymidine uptake. At the same time, the drug slowed the cell cycle progression from the  $G_1/S$  boundary to the  $G_2/M$  phase, hence the lingering population in the S and  $G_2/M$  phases according to flow cytometry.

25                    It is worth mentioning the inhibition of proliferation by LAC was a combinatory effect of cell cycle progress and cell death, the latter possible being the consequence of the former. The later the compound was added when more T cells are activated, a larger proportion of the effect should be attributed to cell death caused by LAC. The extensive cell death for the sample treated with LAC at 40h was not

fully reflected in the flow cytometry (Fig. 6C) as cells with less than 2N DNA. This was due to that the histogram was gated on a region of largely viable cells.

5 The results from this section indicate that the proteasome activity is not required from the G<sub>2</sub>/M to the G<sub>1</sub> phase. It optimizes the progression from the G<sub>1</sub>/S boundary (as defined by the hydroxyurea target point) to the G<sub>2</sub>/M phases, and it is absolutely required for the progression from the G<sub>0</sub> to the S phase.

10 In a specific embodiment of this invention LAC is used to reverse ongoing graft rejection during a rejection episode. Most immunosuppressive drugs do not have the capability to reverse rejection once it begun. The use of LAC overcomes the prior art.

#### 15 **The Proteasome Activity is Essential for CDK2 but not for CDK4 Function**

Cyclin-dependent kinases (CDK) are critical for cell proliferation. CDK4 is essential in the early to mid-G<sub>1</sub> phase to facilitate the S phase entry (Tam et al., 1994, *Oncogene* 9:2663; Lukas et al., 1995, *Oncogene* 10:2125) and CDK2 is critical in the late G<sub>1</sub> as well as throughout the S phase for the cell cycle progression (Van der Heuvel et al., 1993, *Science* 262:2050). We therefore examined the role of the proteasome in CDK4 and CDK2 activities in mitogen-stimulated T cells. In all the models used in this section, LAC was added only once at the beginning of the culture. Consequently, the viability of the LAC-treated cells was good for the first 16h and was reasonable at 40h, and was not a factor that might interfere with the interpretation of the results.

25 As shown in Fig. 7A, the resting T cells had some CDK4 activity, and the activity reached a plateau within 16h of the activation. This was in agreement with the critical role of CDK4 in the early G phase.

Inhibition of the proteasome activity by LAC from 0-16h (LAC added once at 0h) did not affect the CDK4 activity when examined at 16h and 40h (Fig. 7A). This indicates that the induction and maintenance of CDK4 activity during the G1 phase is not proteasome-dependent.

5 In contrast to CDK4, the CDK2 activity was augmented at 16h but the augmentation was more prominent at a later stage close to 40h after the mitogen-stimulation (Fig. 7B), and this reflected its essential role starting from the late G<sub>1</sub> phase and extending to the early S phase. The presence of LAC from 0h to 16h (LAC added once at 0h) significantly inhibited CDK2 activity at 16h and more so at 40h. Therefore, the proteasome activity during the early activation stage (0h-16h) is essential for the activation of the kinase at the G1 phase and early S phase. The unchanged CDK4 activity in the LAC-treated cells at 40h served as an internal control for the repressed CDK2 activity and indicating the latter was not due to the viability problem.

15 Since at the late G<sub>1</sub> phase Cyclin E is the predominant partner of CDK2 (Sherr, 1993, Cell 73:1059), we next examined the Cyclin E-associated CDK activity. As shown in Fig. 7C, in spite that the Cyclin E protein was increased after the LAC treatment (LAC added once at 0h), the Cyclin E-associated kinase activity was almost completely inhibited by LAC. These results indicate that the CDK2 activity, and most likely the Cyclin E-associated CDK2 activity in the late G<sub>1</sub> phase is proteasome-dependent. The results also suggest that the inhibition of the CDK2 activity is probably an important mechanism accountable for the LAC's effect in blocking the S phase entry.

25 It is an embodiment of this invention to have elucidated a downstream target for proteasome activity. That is CDK2, more specifically Cyclin E-associated CDK2 activity. It is also provided that with this knowledge, inhibitors of CDK2 can be used alone or in combination

with proteasome inhibitors. It is further provided that the aforementioned compositions are of a pharmaceutically effective amount to induce apoptosis or for any other cellular or physiological effect. Since CDK4 activity is important in  $G_0$  to  $G_1$ , progression and it is not affected by proteasome activity, it is conceivable that inhibitors for CDK4 can be used in combination with proteasome inhibitors of a pharmaceutically effective amount to achieve additive effect in blocking cell proliferation and in any other relevant cell function.

Inhibitors in this application are defined as any element capable of silencing the activity of a protein at the level of gene transcription, translation, or post-translational modification of the protein as well as elements capable of interfering with the protein. These may include but are not limited to antibody or other ligands, anti-sense or antagonist molecules.

#### **Degradation of Cyclin E but not Cyclin A is Proteasome-Dependent**

It is a specific embodiment of this invention that contacting LAC with CDK2 is inhibitory to CDK2 activity, more particularly it is the inhibitory effect of LAC on Cyclin E. The inhibitory effect of LAC is the disruption of cell cycling.

Oscillation of cyclins during the cell cycle is a mode of regulation for the CDK activities. Since the CDK2 activity is proteasome-dependent, and CDK2 associates predominantly with Cyclin E and cyclin A at the  $G_1/S$  boundary and during the S phase respectively (Pagano et al., 1992, EMBO J. 11:961; Hall et al., 1995, Oncogene 11:1581), we studied the role of the proteasome in degradation of these two cyclins. As shown in Fig. 8A, the Cyclin E level was apparently increased around 40h after PHA stimulation of the T cells, which were then at the  $G_1/S$  boundary. If the activated cells were treated

with HU, the Cyclin E level was significantly enhanced comparing with those treated with PHA alone (Fig. 8A). This reflects a better synchronization at the G<sub>1</sub>/S boundary by HU, and was consistent with our knowledge that the Cyclin E level peaked at the boundary. After the boundary, the Cyclin E level started to decline, and the decline was prevented by LAC (Fig. 8A). This clearly demonstrates that the degradation of Cyclin E is a proteasome-dependent process, although whether the increased Cyclin E level contributes to LAC's effect on the cell cycle is a matter of debate.

For cyclin A, the level was increased around the late G<sub>1</sub> phase after the mitogen stimulation as shown in Fig. 8B. The blockage of the cycle at the G<sub>1</sub>/S boundary with hydroxyurea did not further increase the cyclin A level. However, when the cycle passed the boundary and entered the S phase, the cyclin A level was significantly augmented (Fig. 8B), consistent with the notion that cyclin A is mainly an S phase cyclin. Unlike that of Cyclin E, the level of cyclin A did not decline during the S phase and LAC did not affect the level during this period. This suggests that the proteasome is not involved in cyclin A degradation, at least in the G<sub>1</sub> and S phases, and that LAC's effect on inhibiting cell proliferation is unlikely mediated via the cyclin A levels. The G<sub>1</sub>/S phase synchronized T cells represented activated cells, and prolonged exposure to LAC would cause significant cell death. However, 6h treatment of LAC did not apparently affect the cell viability, while the blockage of Cyclin E degradation but not cyclin A degradation was obvious at that time point. Moreover, cyclin A could be considered as an internal control for Cyclin E indicating that the LAC-induced cell death should not affect the conclusion in this section.

## The Role of Proteasome in Regulating Levels of CDK Inhibitors p27<sup>Kip1</sup> and p21<sup>Cip1</sup>

In a specific embodiment, LAC is capable of suppressing the up regulation of the CDK inhibitor p21<sup>Cip1</sup> and in blocking the degradation of the CDK inhibitor p27<sup>Kip1</sup>.

In addition to the cyclin levels, the CDK activities are also controlled by several low molecular weight inhibitors. We have examined in this study the effect of the proteasome on the CDK inhibitors p27<sup>Kip1</sup> (Hall et al., 1995, supra) and p21<sup>Cip1</sup> (el-Deiry et al., 1993, Cell 75:817). As shown in Fig. 9A, the resting T cells had a high level of p27<sup>Kip1</sup> and the level decreased gradually when the cells moved to the G<sub>1</sub>/S boundary 40h after the mitogen-stimulation. This is in agreement with previous reports (Hengst et al., 1996, Science 271:1861; Nourse et al., 1994, Nature 372:570). The presence of LAC (added once at 0h) significantly blocked the decrease when assayed at 16h, showing that the degradation is a proteasome-dependent process. The blockage was less obvious when assayed at 40h, probably because the gradual loss of LAC activity during the 40h culture. The result suggests that the blocking of p27<sup>Kip1</sup> degradation is a contributing mechanism contributing for the inhibitory effect of LAC on the CDK2 activity. Unlike p27<sup>Kip1</sup>, p21<sup>Cip1</sup> had a low level of expression in resting T cells. The level was rapidly augmented after 16h PHA activation, and the high level was maintained at the G<sub>1</sub>/S boundary at 40h (Fig. 9B). Such an induction suggests that p21<sup>Cip1</sup> might be required in the G phase for roles other than a CDK inhibitor. Interestingly, LAC strongly suppressed the upregulation of p21<sup>Cip1</sup> in the G<sub>1</sub> phase, indicating that the expression of p21<sup>Cip1</sup> is proteasome-dependent, and suggesting that the proteasome might facilitate cell proliferation via its role in p21<sup>Cip1</sup> upregulation during the G<sub>1</sub> phase. In this experiment, LAC was only added once at the beginning of

the culture, and the viability of the treated cells at 16h was good (83~) and should not be a concern in drawing the conclusion.

### **Disruption of Cell-Cell Interaction**

5                   Cell-cell interaction is essential in antigen presentation and in T cell's help to T and B cells. The adhesion molecules are necessary to establish the cell-cell interaction. Blocking the adhesion molecules ICAM-1 and LFA-1 is known to inhibit immune responses and to suppress graft rejection. Our data clearly shows that inhibition of the  
10                   proteasome activity will effectively interfere with the cell-cell interaction during lymphocyte activation in both human (Fig. 10) and mouse (Fig. 11) systems, and the upregulation of an adhesion molecule ICAM-1 is repressed by the proteasome inhibitor lactacystin (Fig. 12). Therefore, inhibition of the proteasome activity will be a useful way to control  
15                   undesirable immune responses during graft rejection, autoimmune diseases, and inflammation.

### **Proteasome Activity is Required for Nitric Oxide Production**

20                   Nitric oxide (NO) produced by macrophages is involved in inflammation and septic shock. We have shown that inhibition of the proteasome activity could effectively repress the endotoxin LPS-induced NO production (Fig. 13). The usefulness of proteasome inhibitors in inflammation and in septic shock is implicated. Fig. 14 demonstrates that proteasome activity is required for NO synthase expression. The addition  
25                   of LAC decreases the expression of mRNA for NO synthase.

### **The Effect of Proteasome on Mitochondrial Function**

Mitochondria are pivotal organelles in the cells and their primary function is to produce ATP via the Krebs cycle coupled to the

oxidative phosphorylation of the respiratory chain. An intact function of mitochondria is also required for proper cell viability. Damage of the mitochondrial membrane potential or release of cytochrome C or other apoptogenic factors from the mitochondria to the cytosol will induce cell death via apoptosis.

In our study, we have found that the electron transport in mitochondria of Jurkat T lymphocytes is dependent on the intact activity of the proteasome. A proteasome-specific inhibitor lactacystin (LAC) could rapidly (within 4h) reduce the electron transport at the complex IV of the respiratory chain, and the effect could be reversed by adding back exogenous cytochrome C (cytoC).

In Fig. 15, the respiration of Jurkat cells treated with LAC for 4h (curve 4) but not for 2h (curve 3) could not be resumed by adding succinate after Complex I blockage, and CCCP failed further to stimulate the respiration as it could in control Jurkat cells and in rat mitochondrial preparation (curves 5 to 6, respectively). Adding rat kidney mitochondria to the blocked reaction results in normal respiration (curve 4), showing the reagents and the oxygen electrode are functional. The results indicate that LAC compromises the electron transport after Complex I.

In Fig. 16, Jurkat cells treated with LAC for 2h (curve 3) had similar  $O_2$  consumption after Complex III, like that of untreated Jurkat cells (curve 2) and rat kidney mitochondria (curve 1). After 4h LAC treatment, the  $O_2$  consumption of the Jurkat cells could not be resumed by ascorbate and TMPD to a level similarly high as that of untreated Jurkat and rat mitochondria, and the decoupling reagent CCCP had no effect in the treated cells (curve 4). Adding back rat kidney mitochondria into the assay could resume the  $O_2$  consumption, showing a functional assay system. Curves 5 to 6 are untreated Jurkat cells and rat kidney mitochondria, respectively, showing normal function of Complex IV. This

result shows that the LAC treatment caused compromised function in the electron transport at Complex IV.

In Fig. 17, Jurkat cells treated with LAC (curve 3) have reduced augmentation of  $O_2$  consumption after the addition of ascorbate and TMPD, compared with untreated Jurkat cells (curve 2) and rat kidney mitochondria (curve 1). FCCP could not further stimulate the respiration, as it could in normal Jurkat cells and rat kidney mitochondria. When exogenous cytochrome c (CytoC) was added to the LAC-treated cells, the respiration resumed to a rate similar to that of untreated Jurkat cells and mitochondria. CytoC had no additive effect in stimulating respiration in normal Jurkat cells and rat mitochondria (curves 2 and 3, respectively).

The implication of aforementioned findings is as follows:

In hyperthyroidism, the mitochondrial activity is overactive due to the effect of the thyroid hormone. This results in many symptoms such as excessive body heat, and imbalance of energy uptake and consumption. The proteasome inhibitors could reduce the rate of mitochondrial respiration and have therapeutic effect to this disease.

In fast-growing cells such as cancer cells or activated lymphocytes, the mitochondria are more active than in normal cells in order to meet the energy requirement of a high metabolic activity of these cells. Consequently, inhibition of the mitochondrial respiration could curb the proliferation of the cancer cells or activated lymphocytes while have less detrimental effects to normal resting cells. In addition, apoptosis could be induced in the cycling cells but not resting cells. Thus, inhibition of the proteasome activity will have therapeutic effect in cancer and in diseases involving lymphocyte activation and proliferation, such as seen in graft rejection and autoimmune diseases.

### **Rapid Assays for A High Through-Put Screening Procedure to Identify Additional Proteasome Inhibitors**

In our study, we have shown that about 70-80% of the chymotrypsin-like activity in the lymphocyte lysates is derived from the proteasome (Fig. 20). In a positive control, LAC at 10  $\mu$ M could inhibit 90% of the 20S proteasome activity which was in a range similar to that of the cell lysates. Increasing the concentration of LAC to 20  $\mu$ M did not further increase the inhibitory effect, suggesting that the LAC concentration used was already saturating. The remaining 10% activity might be derived from non-proteasome proteinases in the 20S proteasome preparation. When 10  $\mu$ M LAC was added to the 70-h cell lysate, it inhibited 73.4%, 76.7% and 86.7% of total chymotrypsin-like activity in the lysates from medium-, PHA- and PHA plus RAPA-treated PBMC, respectively, and those percentages represented the portion of enzymatic activity from the proteasome.

The implication of this finding is that mammalian cell lysates without other purification could be used as a convenient source of proteasomes. Tagged substrates specific for the known proteasome activities, such trypsin-like, chymotrypsin-like, and PGPN activities can be used as displaying parameters. Known compounds could be added into this enzyme/substrate system, and the compound(s) that inhibit(s) one or several aforementioned enzyme activities of the lysate above a certain threshold (for example 40%) will be identified as proteasome inhibitors. These assays could be modified to use purified or partially purified 20S or 26S proteasome as a source of the proteasome enzymes. Since such assays are simple (only three components) and rapid (only several minutes of reaction period), they could be adapted for high through-put screenings, and included in a kit format.

### The Effect of Immunosuppressive Drugs on Proteasome Function

Rapamycin (RAPA) is a potent immunosuppressive drug, and certain of its direct or indirect targets might be of vital importance to the regulation of an immune response. Seven

5 RAPA-sensitive genes are known and one of them encoded a protein with high homology to the  $\alpha$  subunit of a proteasome activator (PA28 $\alpha$ ). This gene was later found to code for the  $\beta$  subunit of the proteasome activator (PA28 $\beta$ ). Activated T and B cells had upregulated PA28 $\beta$  expression at the mRNA level. Such upregulation could be suppressed by RAPA,

10 FK506, and cyclosporin A (CsA). RAPA and FK506 also repressed the upregulated PA28 $\alpha$  messages in PHA-stimulated T cells. At the protein level, RAPA inhibited PA28 $\alpha$  and PA28 $\beta$  in the activated T cells according to immunoblotting and confocal microscopy. Probably as a consequence, there was a fourfold increase of proteasome activities in

15 the PBMC lysate after the PHA activation. RAPA could inhibit the enhanced part of the proteasome activity. Considering the critical role played by the proteasome in degrading regulatory proteins, a proteasome activator is a relevant and important downstream target of rapamycin, and that the immune response could be modulated through the activity of the

20 proteasome.

A lot of efforts have been made to identify direct targets of RAPA. It is now known that RAPA complexes with a 12KD FK506-binding protein (FKBP12) (Harding et al., 1989, Nature 341:371; Siekierka et al., 1989, Nature 341:755). The RAPA-FKBP12 complex then

25 binds to cytoplasmic proteins termed TOR1 and TOR2 (target of rapamycin) in yeast (Kunz et al., 1993, Cell 73:585; Helliwell et al., 1994, Mol. Biol. Cell. 5:105), and FRAP and RAFT1 in mammalian cells (Brown et al., 1994, Nature 369:756; 11). These target proteins have high degree of homology in their primary sequences, and their C-terminal sequences

share certain homology with catalytic domains of both PI-3 kinase and PI-4 kinase.

The mRNA expression of most genes so far studied, whether they are constitutively expressed or induced after stimulation, are not sensitive to RAPA (Tocci et al., 1989, J. Immunol. 143:718; Shan et al., 1994, Int. Immunol. 6:739). It follows that the genes that are sensitive to RAPA at the mRNA level have a good probability of being secondary targets of RAPA and being pivotal in controlling the immune response. Expression of PA28 $\beta$  at mRNA and protein levels was found to be sensitive to RAPA, so was that of the PA28 $\alpha$  subunit which shares a high degree homology with PA28 $\beta$ . It was found that proteasome activity was repressed by the drug.

In HeLa cells, PA28 $\beta$  expression was dramatically upregulated at the mRNA level by IFN $\gamma$  treatment after 24h. This was similar to the regulation of PA28 $\alpha$  (Realini et al., 1994, J. Biol. Chem. 269:20727). When human tonsillar T cells were stimulated by PHA, the PA28 $\beta$  expression was augmented after 20h, and the augmentation could be suppressed by 10nM RAPA as expected (Fig. 18A). In addition, the expression was also sensitive to CsA (1  $\mu$ M) and FK506 (10nM). In tonsillar B cells, SAC and IL-2 upregulated the PA28 $\beta$  mRNA expression, and RAPA was inhibitory (Fig. 18B). Similarly, the mRNA expression of PA28 $\alpha$ , which has a high degree of homology with PA28 $\beta$ , was upregulated in PHA-activated T cells, and the upregulation was repressed by FK506 and RAPA (Fig. 18C).

Expression of PA28 $\beta$  and PA28 $\alpha$  at the protein level was also examined. The result of immunoblotting demonstrated that the activated T cells had increased PA28 $\beta$  compared with resting T cells, and the increase was inhibited in the presence of RAPA (Fig. 19A). Since the anti-PA28 $\alpha$  antiserum did not seem to recognize the denatured proteins,

we used confocal immunofluorescent microscopy to examine the PA28 $\alpha$  protein as well as the PA28 $\beta$  protein in the T cells. The experiment was carried out in an one-way blind fashion, the microscopy operator without being informed of the treatment of the cells. As shown in Fig. 19B, RAPA plus PHA-treated T cells had significantly lower levels of both PA28 $\alpha$  and PA28 $\beta$  proteins compared with T cells treated with PHA alone. We have noticed that although the difference between the PHA-activated T cells in the absence and presence of RAPA was highly significant ( $p < 0.0001$ ), the difference of the numeric values of the mean fluorescence intensity between the two types of cells, especially in the case of PA28 $\beta$ , was rather small. However, there was a high standard deviation in the PHA-treated samples. A closer inspection revealed that about 40% of the cells treated with PHA alone had elevated PA28 $\beta$  and PA28 $\alpha$  signals while the rest had basal level expression. This caused the high standard deviation. Considering that there were 20% non T cells in the T cell preparation, and that PHA does not activate all the T cells in the culture simultaneously, those 40% cells with the high signals probably represented the truly activated T cells. Therefore, the actual difference between the activated and drug-repressed cells could be much bigger than the data presented in the histogram.

Taken together, our data indicates that RAPA inhibits the expression of PA28 $\alpha$  and PA28 $\beta$  at both mRNA and protein levels. The inhibition of the PA28 mRNAs is a likely cause for the observed decrease of the corresponding proteins. However, we could not exclude the possibility that RAPA might also act directly at the translation level for PA28 $\alpha$  and PA28 $\beta$ .

In as much as PHA could upregulate and RAPA could repress expression of the proteasome activator PA28 $\beta$  and PA28 $\alpha$  in the T cells, it is logical to examine changes of proteasome activity in these

cells. PBMC lysates were assayed for their proteinase activity at pH 8.2 which favors the proteasome activity, using a chymotrypsin substrate as a representative parameter. Forty and seventy hours after stimulation by a T cell mitogen PHA, the chymotrypsin-like activity in the PBMC increased 2.1 fold and 3.8 fold, respectively (Fig. 20A). RAPA at 10nM repressed 23.1% and 41.1% the activity in the PBMC, respectively, at these time points.

We then tried to determine the part of enzyme activity in the lysates conferred by the proteasome. In a positive control, LAC at 10  $\mu$ M could inhibit 90% of the 20S proteasome activity which was in the range similar to that of the cell lysates (Fig. 20B). Increasing the concentration of LAC to 20  $\mu$ M did not further increase the inhibitory effect, suggesting that the LAC concentration used was already saturating. The remaining 10% activity might be derived from non-proteasome proteinases in the 20S proteasome preparation. When 10  $\mu$ M LAC was added to the 70h cell lysate, it inhibited 73.4%, 76.7% and 86.7% of total chymotrypsin-like activity in the lysates from medium-, PHA- and PHA plus RAPA-treated PBMC, respectively, and those percentages represented the portion of enzymatic activity from the proteasome (Fig. 20B). The net proteasome activity increased by 4 fold from  $42.6 \times 10^3$  units/20  $\mu$ g protein in unstimulated cells to  $170.3 \times 10^3$  units/20  $\mu$ g protein in the PHA-activated cells. In RAPA-treated cells, the activity decreased to  $113.2 \times 10^3$  units/20  $\mu$ g protein. This equated to 33.6% inhibition of the total activity, or 44.7% of the augmented proteasome activity in the PHA-treated PBMC. It is therefore demonstrated that RAPA could inhibit the enhanced proteasome activity during T cell activation.

It is an embodiment of this invention to have identified known immunosuppressive drugs including rapamycin, FK506 and

cyclosporin A as inhibitors of enhanced proteasome activity. It is therefore a specific embodiment of this invention for providing these immunosuppressive drugs of a pharmaceutically effective amount and in combination with specific proteasome inhibitors of a pharmaceutically effective amount, as an example but not limited to LAC or its analogues to achieve an additive effect in blocking cell proliferation and any other relevant cell function. Such combinations as described can be used but are not limited to the treatment of cancer, graft rejection and autoimmune diseases.

#### **Elimination of alloantigen-specific response**

The results of the functional assay shown in Figure 21 suggests, that there is clonal deletion of BALB/c-specific T cells when proteasome activity of alloantigen-activated T cells are inhibited for a brief period. The consequences of this finding suggests that proteasome inhibitors can be administered when specific T cells are activated, thereby potentially eliminating the activity of specifically activated T cells while leaving non-activated T cells intact. It is therefore an embodiment of this invention to use proteasome inhibitors, particularly lactacystin in transplantation and autoimmune diseases where certain undesirable activated T cells can be repressed or eliminated and the rest of the T cell population is generally unaffected by such inhibitors.

#### **The effect of caspase inhibitor zVAD.fmk. on LAC-induced DNA fragmentation**

The effect of lactacystin as an apoptotic agent in Jurkat cells is shown in Figure 22, by the typical apoptotic sign of DNA laddering. Addition of the broad spectrum caspase inhibitor zVAD.fms demonstrated an inhibitory effect on DNA fragmentation that is

concentration responsive. This result indicates that the lactacystin-induced apoptosis in Jurkat cells is caspase-dependent.

#### **The effect of lactacystin on a pro-apoptotic Bcl-2 family member, Bik**

5                   The results shown in Figure 23 panel A, show that Bik, Bax, Bak, and Bad are predominantly located in the mitochondrial fraction. Treatment with lactacystin does not appear to have altered the amounts of Bax, Bak and Bad (Fig. 23 panels A and B). There is however a demonstrable increase in the amount of Bik in the lactacystin treated Jurkat cells after 4 h, 5 h and 7 h (the first row of panels A and B), when compared with untreated cells. The results shown in Fig. 23, suggests that under normal circumstances, Bik is degraded rapidly by the proteasome. Blocking of this degradation by a proteasome inhibitor, allows the pro-apoptotic Bcl-2 member to accumulate. The accumulation of Bik may possibly tip the balance between pro- and anti-apoptotic factors favoring apoptosis.

#### **The effect of overexpression of Bcl-xL, an anti-apoptotic Bcl-2 family member**

20                   The human B cell line Namalwa stably transfected with an anti-apoptotic Bcl-2 family member Bcl-xL, was shown to be more resistant to the proteasome inhibitor lactacystin than the untransfected, wild type Namalwa cells. The results shown in Figure 24 indicate that the transfected cells have demonstrably less DNA fragmentation at the different intervals and lactacystin concentrations tested. This suggests that the overexpression of Bcl-xL protein has probably counteracted the effect of the accumulation of the pro-apoptotic Bik. In this manner the Namalwa cells are somewhat protected from undergoing apoptosis.

In an additional experiment, Jurkat cells, wild type Namalwa cells and Bcl-xL transfected Namalwa cells were treated with staurosporine and lactacystin for 6 H. Proteins from the mitochondrial fraction of these cells were analyzed by immunoblotting for the amount of Bik, Bcl-xL, Bax, and Bak. The results summarized in Figure 25, show that Bik accumulates in the Namalwa cells (panel B, lane 3) and Jurkat cells (panel A lane 2) after a 6 hour lactacystin treatment. This accumulation is due to the inhibition of proteasome activity and indicates that the degradation of Bik via the proteasome is a general phenomenon. The elevated amount of Bik, is likely a mechanism of lactacystin-induced apoptosis in the Jurkat and Namalwa cells. The accumulation of Bik was only observed in the lactacystin-treated but not in staurosporine treated cells, even though staurosporine could equally induce apoptosis in these cells. The expression of exogenous anti-apoptotic Bcl-2 member Bcl-xL as expected, was not detected in Jurkat cells and wild type Namalwa cells (panels A and B). The Bcl-xL overexpression was obvious in the transfected Namalwa cells (panel C). Moreover, there was an accumulation of Bcl-xL after lactacystin treatment, showing that under normal circumstances the degradation of Bcl-xL, like Bic is also rapid and depends on proteasome activity. These results suggest that the Bcl-xL-transfected Namalwa cells have two mechanisms to protect them from proteasome inhibitor-induced apoptosis. First the overexpression of the anti-apoptotic Bcl-xL changes the balance between pro- and anti-apoptotic factors and favors the anti-apoptotic factors. Second, after treatment with lactacystin, there is an accumulation of Bcl-xL which imparts additional weight to the anti-apoptotic factors.

Thus, the balance between the pro- and anti-apoptotic factors in cells is crucial in deciding the fate of these cells. Certain apoptosis-related factors have a short half life and their degradation is via the proteasome machinery. Therefore, modulating the proteasome activity with proteasome inhibitors is a useful way to control the balance between the pro- and anti-apoptotic factors. This control provides the means to induce cells into apoptosis or continued survival.

Accordingly, it is an additional embodiment of this invention to provide the means to balance between pro-apoptotic and anti-apoptotic factors in a cell using proteasome inhibitors, particularly lactacystin.

The present invention is illustrated in further detail by the following non-limiting examples.

**EXAMPLE 1****Reagents**

5 RPMI 1640, FCS, penicillin-streptomycin, and L-glutamine were  
 purchased from Life Technologies (Burlington, Ontario, Canada).  
 Lymphoprep was purchased from NYCOMED (Oslo, Norway). PHA,  
 hydroxyurea, nocodazole, and histone H1 were from Sigma (St. Louis,  
 MO). Staphylococcus aureus Cowan I (SAC) were obtained from  
 Calbiochem (La Jolla, CA), and lactacystin from Dr. E.J. Corey (25).  
 10 Human rIL-2 was from La Roche (Nutley, NJ), and anti-CD3 mAb OKT3  
 was from ATCC (Rockville, MD). FITC-conjugated anti-CD3 mAb(clone  
 SFCIRW2-8C8) and PE-conjugated anti-CD25 mAb (clone IHT44H3)  
 were from Coulter (Miami, FL). Anti-CD28 mAb (clone 9.3) was a gift from  
 Dr. P. Linsley (26). A fluorogenic chymotrypsin substrate SLLVY-MCA  
 15 was from Peninsula Laboratories (Belmont, CA). Rabbit antisera against  
 cyclin A, Cyclin E, p27<sup>Kip1</sup>, p21<sup>Cip1</sup>, CDK2 and CDK4 were purchased from  
 Santa Cruz Biotech (Santa Cruz, CA). [ $\gamma$ -<sup>32</sup>P]ATP (3000  $\mu$ Ci/mmol) and  
 [<sup>125</sup>I] protein A (30mCi/mg protein) were ordered from Amersham  
 (Oakville, Ontario, Canada), and [Methyl-<sup>3</sup>H] thymidine (2Ci/mmol) was  
 20 from ICN (Irvine, CA).

**Cell culture**

Peripheral blood mononuclear cells (PBMC) and tonsillar T cells were  
 prepared as described before (Luo et al., 1992, Transplantation **53**:1071;  
 25 Luo et al., 1993, Clin. & Exp. Immunol. **94**:371). The cells were cultured  
 in RPMI 1640 supplemented with 10% FCS, L-glutamine and antibiotics.  
<sup>3</sup>H-thymidine uptake was carried out as described previously (Luo et al.,  
 1992, supra; Luo et al., 1993, supra).

### DNA fragmentation assay

The assay was performed according to a protocol described by Liu et al (Liu et al., 1997, Cell. 89:175) with some modifications. Briefly, 2-6 million cells were re-suspended in 50  $\mu$ l PBS followed by 300  $\mu$ l lysis buffer (100 mM Tris-HCl, pH 8.0, 5 mM EDTA, 0.2 M NaCl, 0.2% w/v SDS, and 0.2 mg/ml proteinase K). After overnight incubation at 37°C, 350  $\mu$ l of 3M NaCl was added to the mixture and cell debris was removed by centrifugation at 13000 g for 20 min at room temperature. DNA in the supernatant was precipitated with an equal volume of 100% ethanol. The pellet was washed with cold 70% ethanol and then dissolved in 20  $\mu$ l of TE containing 0.2 mg/ml RNase A. After incubation at 37°C for 2 h, the DNA was resolved on 2% agarose gel and visualized with ethidium bromide staining.

### 15 Electron microscopy

T cells and Jurkat cells were examined by electron microscopy as described by Tsao and Duguid (Tsao et al., 1987, Exp. Cell Res. 168:365).

### 20 Flow cytometry for IL-2R $\alpha$

Two-color staining with FITC-anti-CD3 and PE-anti-CD25 was performed on tonsillar T cells. The method was described before (Luo et al., 1993, supra).

### 25 Proteinase assay

Jurkat cells were cultured with various treatments and were harvested and sonicated in 300  $\mu$ l PBS on ice for 40 sec. Twenty micrograms of protein per sample from the cleared lysates were supplemented to 100  $\mu$ l

with 0.1M Tris buffer (pH 8.2). The fluorogenic chymotrypsin substrate sLLVY-MCA was added at a final concentration of 10nM. The samples were incubated at 37°C for 15 min and the reaction was terminated by adding 4 µl 2.5M HCl. The samples were then diluted to 2ml with 0.1M Tris pH 8.2, and measured for their fluorescence intensity by a PTI fluorometer (Photo Technology International, South Brunswick, NJ). The excitation wavelength was 380nm, and the emission wavelength 440nm.

#### Cell cycle synchronization of T cells and Jurkat cells

Tonsillar T cells were cultured in the presence of 2 µg/ml PHA and 1mM hydroxyurea for 40h. The cells thus treated were synchronized at the G<sub>1</sub>/S phase. The synchronization was released by washing out hydroxyurea, and the cells were cultured in medium for additional 6-22h according to the need of each experiment. The synchronization of Jurkat cells was described in our previous publication (Shan et al., 1994, Int. Immunol. 6:739). Briefly, the Jurkat cells were starved in isoleucine deficient medium for 24h followed by 16h treatment with 2mM hydroxyurea (HU). Cells thus treated were synchronized at the G<sub>1</sub>/S boundary. For synchronization at the G<sub>2</sub>/M boundary, the G<sub>1</sub>/S synchronized cells were released from hydroxyurea and cultured in regular medium for 6h, and then treated with 0.1 µg/ml nocodazole for 16h. The cells were then synchronized at the G<sub>2</sub>/M boundary.

#### Cell cycle analysis

Flow cytometry was employed for cell cycle analysis for T cells and Jurkat cells as described before (Shan et al., 1994, supra) using propidium iodide staining.

### Immunoblotting

Immunoblotting was employed to evaluate the levels of Cyclin E, cyclin A, p21<sup>Cip1</sup> and p27<sup>Kip1</sup>. The general protocol was described in our previous publication (Chen et al., 1996, J. Immunol. 157:4297). Briefly, lymphocytes were lysed in the presence of proteinase inhibitors. The cleared lysates were quantitated for protein concentrations. An equal amount of lysate proteins (40 µg) of each sample was resolved by 10% SDS-PAGE and was transferred to PVDF membranes (Millipore, Bedford, MA). The membranes were then blocked with 5% milk, and hybridized with rabbit antisera against Cyclin E, cyclin A, p27<sup>Kip1</sup> and p21<sup>Cip1</sup> at dilutions suggested by the manufacturer. The signals on the membrane were detected by [<sup>125</sup>I]-protein A followed by autoradiography.

### Immunoprecipitation and the kinase assay

Lymphocytes were lysed by a lysis buffer as used in the immunoblotting (Chen et al., 1996, supra), and cleared lysates were quantitated for their protein content. For immunoprecipitation, 50 µl of rabbit antisera against CDK2, CDK4 or Cyclin E were added to the lysates equivalent to 20 or 40 µg protein depending on the experiment. After 2h incubation at 4°C, the immune complexes were recovered by protein A-conjugated Sepharose (Pharmacia Biotech, Montreal, Québec, Canada). The immune complexes bound to protein A-Sepharose were extensively washed in a lysis buffer without detergents or EDTA, and resuspended in 50 µl of kinase reaction buffer (100mM NaCl, 20mM HEPES, pH7.5, 5mM MnCl<sub>2</sub>, 5mM MgCl<sub>2</sub>, 25 µM cold ATP, 2.5 µCi [γ-<sup>32</sup>P] ATP, and 3 µg histone H1 as a substrate). The reaction was carried out for 10 min at room temperature, and stopped by adding the SDS-PAGE loading buffer. After boiling for 3 min, the samples were subjected to 10% SDS-PAGE.

The proteins were then transferred to PVDF membranes and the signals were detected by autoradiography.

## **EXAMPLE 2**

5

### **Assays Measuring Nitric Oxide Production**

#### **Macrophage Preparation and Culture**

BALB/c mice were injected i.p. with 3ml of 3% thioglycollate broth. Three days later, peritoneal exudate macrophages of the mice were harvested and washed at 170 g for 10 min at 4° C. The macrophages were cultured in Teflon vials (2cm in diameter) at  $4 \times 10^6/2\text{ml}$  with various reagents (LPS, 2  $\mu\text{g/ml}$ ; IFN $\gamma$ , 100u/ml; LAC, 0.62-5  $\mu\text{M}$  for the nitric oxide assay and 5  $\mu\text{M}$  for the Northern blot assay).

#### **Nitric Oxide Measurement**

The nitrite concentration in the culture supernatant was measured as a way to indirectly reflect the nitric oxide level following a method described by Ding et al ( Ding et al., 1988, J. Immunology 141:2407). Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activation cytokines and evidence for independent production. Briefly, 100  $\mu\text{l}$  of supernatants collected from 48h macrophage cultures was incubated with an equal volume of the Griess reagent (1% sulfanamide/ 0.1% naphthylethylene diamine dihydrochloride/ 2.5%  $\text{H}_3\text{PO}_4$  )at room temperature for 10 min in 96-well microtitration plates, the O.D. was measured at 550nm. Sodium nitrite of various concentrations were used to construct standard curves.

#### **Northern Blot Analysis of iNOS Expression**

The expression of inducible nitric oxide synthase at the mRNA level was analyzed by Northern blot as described in our previous publication (Shan et al., 1994, J., International Immunology 6:739). After an overnight culture, the mouse macrophages were harvested and their total cellular

5 RNA was extracted with the guanidine/CsCl method. The RNA (10 µg/lane) was resolved in 1% agarose-formaldehyde gels and blotted onto nylon membranes. A 562-bp fragment corresponding to the mouse iNOS cDNA (Xie et al., 1992, Science 256:225) was obtained by reverse transcription/PCR using the mouse macrophages total RNA as templates.

10 The fragment was labeled with <sup>32</sup>P with random primers and used as a probe for the Northern blot.

### **EXAMPLE 3**

#### **15 Respiration of Jurkat Cells**

##### **Preparation of mitochondria**

Rat liver of rat kidney proximal tubules mitochondria were isolated by differential centrifugation in a medium containing 250 mM sucrose, 1 mM HEPES-Tris, 250 µM EDTA (pH 7.5). The last washing of the

20 mitochondria was performed in the same medium without EDTA. Protein concentration of the mitochondrial suspension was measured after solubilization of the membranes in 0.1% SDS with the Pierce-BCA (bicinchroninic acid) protein assay reagent (Pierce, Rockford, IL, USA), using bovine serum albumin as a standard.

25

##### **Respiration Measurements**

The Jurkat Cells (JC) (30x10<sup>6</sup>/ml) or rat kidney proximal tubules mitochondria (RKM) (0.5 mg of protein/ml) were incubated in 1 ml

measuring chamber at 37°C in a respiration buffer containing 200 mM sucrose, 5 mM MgCl<sub>2</sub>, 5 mM KH<sub>2</sub>PO<sub>4</sub>, and 30 mM HEPES-Tris (pH 7.5). During respiration experiments following substrates and inhibitors were used: 0.005% Digitonine (Dig); 10 mM Succinate (Suc); 1 mM Ascorbate (Asc); 0.4 mM tetramethyl-p- phenylenediamine (TMPD); 1 µM CCCP, 1 µM FCCP; 0.1 µM Rotenone (Rot); 50 nM Antimycin A (Anti); 1 mM KCN; 100 µM Cytochrome C (Cyt C).

The respiration rate of the Jurkat Cells and mitochondria was measured polarographically with a Clarke oxygen electrode (Yellow Springs Instruments, Yellow Springs, OH, USA) using 1 ml thermostated chamber. Oxygen concentration was calibrated with air-saturated buffer using Hypoxanthine - Xanthine Oxidase - Catalase system ("chemical zero"). Oxygen consumption was continuously recorded using a "MacLab/8" (Analog Digital Instruments, USA) connected to a Macintosh SE computer and the MacLab Chart v.3.3.4 software. Rates of oxygen consumption are expressed as ng-atoms of oxygen/min.

#### **EXAMPLE 4**

##### **The effect of immunosuppressive drugs**

###### **Cell culture**

PBMC were prepared by Lymphoprep gradient as described before (Luo et al., 1993, Clin. Exp. Immunol. 94:371; Shan et al., 1994, supra).

Tonsillar T cells were prepared by one cycle of SRBC rosetting and such preparation contained 80-85% CD3<sup>+</sup> cells. The remaining tonsillar cells were referred to as the tonsillar B cells, which were about 90% CD20<sup>+</sup> cells.

### Northern blot analysis

The method is described in our previous publication (Shan et al., 1994, supra). Tissue or lymphocyte total RNA was extracted with the guanidine/CsCl method and used in the Northern blot analysis. A 358-bp  
 5 fragment corresponding to positions -14 to 314 of the PA28 $\beta$  cDNA (Ahn et al., 1995, FEBS Lett. 366:37) from clone 5F2 was labeled with <sup>32</sup>p using random primers and was used as a probe for PA28 $\beta$  messages. A 400-bp fragment corresponding to positions between 267 and 666 of the PA28 $\alpha$  cDNA (Realini et al., 1994, supra) was obtained with RT-PCR and  
 10 was used as a probe for PA28 $\alpha$  messages. The 5' and 3' primers for the RT-PCR were GAAGAAGGGGGAGGATGA and AGCATTGCGGATCTCCAT, respectively.

### Immunoblotting

15 T cell lysates (40  $\mu$ g protein/sample) were separated on 12% SDS-PAGE, and blotted onto PVDF membranes. The membranes were then hybridized with rabbit anti-PA28 $\beta$  antiserum (Ahn et al. 1996, J. Biol. Chem. 271:18237) followed by <sup>125</sup>I-protein A. Detailed methods were described previously (Chen et al., 1996, J. Immunol. 157:4297).

20

### Confocal immunofluorescent microscopy

Cultured tonsillar T cells were stained with rabbit anti-PA28 $\beta$  antiserum (1:1000 dilution) or anti-PA28 $\alpha$  antiserum (1:200 dilution) followed by biotin-conjugated goat anti-rabbit IgG (1:100 dilution, Boehringer  
 25 Mannheim, Montreal, QC) and streptavidin-fluorescein. The immunofluorescence of whole cells was examined and quantified with confocal microscopy as detailed before (Chen et al., 1997, J. Immunol. 159:905).

### Proteinase assay

PBMC were cultured with or without PHA (2 µg/ml) and RAPA (10nM). After 16h-70h, the cells were harvested and sonicated in 300 µl PBS on ice for 40 sec. Twenty micrograms of protein per sample from the cleared lysates were supplemented to 100 µl with 0.1M Tris buffer (pH 8.2). A proteasome-specific inhibitor lactacystin (Omura et al., 1991, J. Antibiot. (Tokyo) 44:113; Fentenay et al., 1995, Science 268:726) was added at a final concentration of 10nM in some samples as indicated. The samples were incubated on ice for 15 min, and fluorogenic chymotrypsin substrate sLLVY-MCA was then added at a final concentration of 10nM. The 20S proteasome, which was prepared as previously described (Friguet et al, 1994, J. Biol. Chem. 269:21639), was used as a positive control in place of cell lysates. The samples were incubated at 37°C for 15 min and the reaction was terminated by adding 4 µl 2.5M HCl. The samples were then diluted to 2ml with 0.1M Tris pH8.2, and measured for their fluorescent intensity by a PTI fluorometer (Photo Technology International, South Brunswick, NJ). The excitation wavelength was 380 nm, and the emission wavelength 440 nm.

### Conclusion

Although the present invention has been described hereinabove by way of preferred embodiments thereof, it can be modified, without departing from the spirit and nature of the subject invention. Any such modification is under the scope of this invention as defined in the appended claims.

WHAT IS CLAIMED IS:

1. A composition for reversing an ongoing adverse immune response in a  
5 patient, which comprises a therapeutically effective amount of a proteasome inhibitor and a pharmaceutically acceptable carrier.
2. The composition of claim 1, wherein said reversal of said immune response is a consequence of administering said proteasome inhibitor after an antigenic  
10 activation of T-cells, said inhibitor reduces activated T-cells, thereby reversing said immune response.
3. The composition of claim 2, wherein said adverse immune response is an autoimmune disease.  
15
4. The composition of claim 2, wherein said adverse immune response is a graft rejection.
5. The composition as defined in any one of claims 1 to 4, which is to be  
20 administered to said patient, once the patient's T cells are mostly activated during said adverse immune response.
6. The composition of any one of claims 1 to 5, wherein said proteasome inhibitor is lactocystin or an analogue thereof.  
25
7. The composition of any one of claims 4 to 6, which is to be administered to said patient at least 24h after a graft transplantation.
8. The composition of any one of claims 1 to 7, further comprising an immuno-  
30 suppressive drug.
9. The composition of claim 8, wherein said immuno-suppressive drug is

00341009-002599

selected from the group consisting of cyclosporin A, rapamycin and FK506.

10. A composition which comprises an effective amount of a proteasome inhibitor for disrupting mitochondrial function by blocking electron transport and/or  
5 inducing cytochrome C leakage from the mitochondria, which results in caspase activation and leads to cell apoptosis.

11. The composition of claim 10, wherein said proteasome inhibitor is lactocystin or an analogue thereof.  
10

12. The composition of claim 11, which alleviates a pathological condition having high mitochondrial activity.

13. The composition of claim 10 or 11, for the treatment of a pathological  
15 condition selected from the group consisting of cancer, inflammation and adverse immune response.

14. A composition for disrupting nitric oxide synthesis by inhibiting nitric oxide synthase gene expression, which comprises an effective amount of a proteasome  
20 inhibitor.

15. The composition of claim 14, wherein said proteasome inhibitor is lactocystin or an analogue thereof.

25 16. The composition of claim 15, wherein said composition alleviates a pathological condition having upregulated nitric oxide synthase expression.

17. The composition of claim 16, wherein said pathological condition is inflammation or septic shock.  
30

18. A method for screening a compound for proteasome inhibition activity, which comprises: obtaining a mammalian cell lysate comprising proteasomes, a

partially purified proteasomes preparation or a purified proteasomes preparation; tagging at least one peptide substrate specific to a known proteasome protease activity; combining said proteasomes and said at least one tagged peptide substrate; contacting the so combined proteasomes/tagged peptide substrate with  
5 said compound; said at least one tagged peptide substrate fails to release tag if said compound is a proteasome inhibitor, and detecting a decrease or absence of the released tag in the presence of said compound relating to the released tag in the absence of said compound as an indication of proteasome inhibition activity for said compound.

10

19. The method of claim 18, wherein said at least one tagged peptide substrate is a fluorogenic peptide.

20. The method of claim 18 or 19, wherein said proteasome protease activity  
15 is trypsin-like chymotrypsin-like or peptidylglutamyl-peptide hydrolyzing activity.

09341009 032399  
55530 6074269



ABSTRACT OF THE INVENTION



The present invention relates to compositions comprising proteasome inhibitors, such as lactocystin and analogues thereof. These compositions are used for the following purposes: (1) to disrupt mitochondrial function (useful against cancer, inflammation, adverse immune reaction and hyperthyroidism), (2) to disrupt nitric oxide synthesis (useful against inflammation and septic shock), and (3) to reverse ongoing adverse immune reactions, such as autoimmune diseases and graft rejection. In the later case, the compositions are administered once the patients' T cells are mostly activated. Proteasome inhibitors can also be combined to immuno-suppressive drugs like rapamycin, cyclosporin A and FK506. Finally, a method for screening a compound having a proteasome inhibition activity is also disclosed and claimed.

"Express Mail" mailing label number EL353244453US  
 Date of Deposit June 29, 1999  
 This document has been deposited with the United States Patent and Trademark Office to comply with 35 U.S.C. 101 and 35 U.S.C. 102(b) and to address the requirements of the United States Patent and Trademark Office, Washington, D.C. 20231  
Thirumala V. R.  
 printed name  
Thirumala V. R.  
 Signature



09341009-002599

1/36



FIG - 1CFIG - 1D

3/36



4/36




FIG. 2C

5/36




Fig. 2D






Fig. 2E

6/36

Fi 3


005200" 0004E60

7/36



$^3\text{H}$ -Thymidine incorporation (CPM)


Fig. 4A




hours after wash out Lac

Fig. 4B

8/36

FIG. 4C

# Gated CD3+ Cells






CD25

Med

PHA

PHA+LAC

9/36




CD25

FIG - 5

10/36


Medium LAC



Percentage of cells in S/G2/M and G1 phases

	Med		LAC	
	S/G2/M	G1	S/G2/M	G1
G2/M (0h)	82.6	17.4		
4h	33.0	67.0	40.2	59.8
8h	41.9	58.1	36.5	63.5


~~7357~~ - 6A



W. J.

12/36


PHA



DNA content

FEF-6C

13/36

Fig. 60

14/36

PHA

16h

40h

Resting

LAC 0-16h

LAC 0-40h



Figure 7A

PHA

16H

40H

Resting

LAC

LAC



Figure 7B


Med PHA PHA+LAC PHA+LAC

↓  
Cyclin E


III

72:77

16/36



FIIB



FIIB

665280" 600T4E60

17/36

PHA

	16h	40h	64h
Resting			
LAC 0-16h			
LAC 0-40h			
LAC 40-64h			

← p27kip1

Fi - 9A

16 H	40 H
Resting	
PHA	
PHA+LAC	
PHA	
PHA+LAC	

Resting  
PHA  
PHA+LAC  
PHA  
PHA+LAC

← P21CIP1


Fi - 9B

09/341009 665280

18/36



FiE - 10A






FiE - 10B



FiE - 10C

665230" 60074E60

19/36

Fig. 11AFig. 11BFig. 11C

20/36





Figure 12

21/36

Fig. 13

22/36

28S-  
18S-  
MED LPS LPS+LAC  
→ iNOS



FIG - 14

23/36




FIG - 15B




FIG - 15A

24/36




Fig. 16B






Fig. 16A


25/36



26/36




18S



18S -

← hPA28β



18S

09341009, 082599

16H

MEU PHA PHA+FK506  
PHA PHA+RAPA

18S -

PA28 $\alpha$



787 - 18C

28/36








Fig. 19B

29/36




30/36



One way MLR  
(C57BL/6 stimulated  
with BALB/c)


Lac (3h)

Restimulate with  
BALB/c or C3H



09341009 082549

Control 6h  
Z-VAD.fmk (33.3uM)  
LAC (33.3uM)  
LAC+Z-VAD.fmk (11.1uM)  
LAC+Z-VAD.fmk (3.7uM)  
LAC+Z-VAD.fmk (1.2uM)  
LAC+Z-VAD.fmk (0.4uM)



kb

0.85 -

0.5 -

Fig. 22

32/36









Fig. 23B

Fig. 23A





35/36

FI - 24E



# MERCHANT & GOULD

## United States Patent Application

### COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Insert TITLE of invention

The Use of Proteasome Inhibitors for Treating Cancer,  
Inflammation, Autoimmune Disease, Graft Rejection and  
Septic Shock

Check a or b

The specification of which

a. ☐ is attached hereto

b. ☒ was filed on June 29, 1999

If "b" checked, complete

as application serial no. \_\_\_\_\_

and was amended on \_\_\_\_\_ (if applicable)

(in the case of PCT-filed application)

If PCT Application

Insert int. application  
number & filing date

described and claimed in international no. PCT/CA98/01010 filed 29 October 1998

and as amended on N/A (if any), which I have reviewed and for which I solicit a United States patent.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a). (Reprinted on back side).

I hereby claim foreign priority benefits under Title 35, United States Code, § 19/365 of any foreign application(s) for patent of inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on the basis of which priority is claimed:

a. ☐ no such applications have been filed.

b. ☒ such applications have been filed as follows:

FOREIGN APPLICATION(S), IF ANY, CLAIMING PRIORITY UNDER 35 USC § 119			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
CA	2,219,867	31 Octobre 1997	
ALL FOREIGN APPLICATION(S), IF ANY, FILED BEFORE THE PRIORITY APPLICATION(S)			
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

I hereby claim the benefit under Title 35, United States Code, § 120/365 of any United States and PCT international application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)

For Continuation-in-Part  
(CIP) Applications, complete

§ 1.56 Duty to disclose information material to patentability.

(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability of a claim that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by § 97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:

- (1) prior art cited in search reports of a foreign patent office in a counterpart application, and
- (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.

(b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

(1) It establishes, by itself or in combination with other information, a prima facie case of unpatentability of a claim;

or

(2) It refutes, or is inconsistent with, a position the applicant takes in:

- (i) Opposing an argument of unpatentability relied on by the Office, or
- (ii) Asserting an argument of patentability.

A prima facie case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability.

(c) Individuals associated with the filing or prosecution of a patent application within the meaning of this section are:

- (1) Each inventor named in the application;
- (2) Each attorney or agent who prepares or prosecutes the application; and
- (3) Every other person who is substantively involved in the preparation or prosecution of the application and who is associated with the inventor, with the assignee or with anyone to whom there is an obligation to assign the application.

(d) Individuals other than the attorney, agent or inventor may comply with this section by disclosing information to the attorney, agent, or inventor.

I hereby appoint the following attorney(s) and/or patent agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith:

Albrecht, John W. Reg. No. 40,481	Gorman, Alan G Reg. No. 28,828	Reg. No. 38,472	Pauly, Daniel M. Reg. No. 40,123
Anderson, Gregg I. Reg. No. 42,264	Gould, John D Reg. No. 41,804	Reg. No. 18,223	Phunkett, Theodore Reg. No. 37,209
Ansems, Gregory M. Reg. No. 32,960	Gresens, John J. Reg. No. 27,612	Reg. No. 33,112	Pystel, Melissa J. Reg. No. 37,209
Beard, John L. Reg. No. 29,249	Hamre, Curtis B Reg. No. 41,622	Reg. No. 29,165	Reich, John C. Reg. No. 37,203
Berman, Charles Reg. No. 31,329	Hillson, Randall A. Reg. No. 17,426	Reg. No. 11,838	Reiland, Earl D. Reg. No. 25,767
Black, Bruce Reg. No. 34,130	Johnston, Scott W. Reg. No. 32,404	Reg. No. 39,721	Rittmaster, Ted R. Reg. No. 32,933
Blasdel, Thomas L. Reg. No. 25,959	Kastelic, Joseph M. Reg. No. 33,924	Reg. No. 37,160	Schmaltz, David G. Reg. No. 39,828
Bogucki, Raymond A. Reg. No. 33,093	Kettelberger, Denise Reg. No. 30,247	Reg. No. 40,684	Schuman, Mark D. Reg. No. 31,197
Bruess, Steven C. Reg. No. 26,652	Knearl, Homer L. Reg. No. 25,968	Reg. No. 31,535	Schumann, Michael D. Reg. No. 30,422
Byrne, Linda M. Reg. No. 40,579	Komandur, Janaki Reg. No. 42,157	Reg. No. 36,848	Sebald, Gregory A. Reg. No. 33,280
Carlson, Alan G. Reg. No. 28,707	Kowalchuk, Katherine M. Reg. No. 20,187	Reg. No. P-44,197	Skoog, Mark T. Reg. No. 40,178
Carter, Charles G. Reg. No. 39,634	Kubota, Glenn M. Reg. No. 39,667	Reg. No. 38,946	Soderberg, Richard Reg. No. P-43,352
Caspers, Philip P. Reg. No. 30,247	Lacy, Paul A. Reg. No. 32,612	Reg. No. 40,443	Sumner, John P. Reg. No. 29,114
Chiapetta, James R. Reg. No. 26,652	Larson, James A. Reg. No. 36,414	Reg. No. 29,555	Summers, John S. Reg. No. 24,216
Clifford, John A. Reg. No. 25,968	Lasky, Michael B. Reg. No. 40,579	Reg. No. 40,066	Tellekson, David K. Reg. No. 32,314
Cochran, William W. Reg. No. 34,994	Liepa, Mara E. Reg. No. 40,201	Reg. No. 40,201	Trembath, Jon R. Reg. No. 38,344
Daignault, Ronald A. Reg. No. 40,579	Lindquist, Timothy A. Reg. No. 36,204	Reg. No. 36,204	Underhill, Albert L. Reg. No. 27,403
Daley, Dennis R. Reg. No. 42,157	Lynch, David W. Reg. No. 35,600	Reg. No. 37,674	Vandenburgh, J. Derek Reg. No. 32,179
Dalglish, Leslie E. Reg. No. 28,707	Marschang, Diane L. Reg. No. 32,044	Reg. No. 32,044	Vrandenburgh, Anna M. Reg. No. 39,868
Daulton, Julie R. Reg. No. 20,187	McDaniel, Karen D. Reg. No. 40,300	Reg. No. 40,099	Welter, Paul A. Reg. No. 20,890
DeVries Smith, Kate Reg. No. 39,634	McDonald, Daniel W. Reg. No. 37,674	Reg. No. P-43,790	Whipps, Brian Reg. No. P-43,261
DiPietro, Mark J. Reg. No. 32,612	McIntyre, Iain A. Reg. No. 30,300	Reg. No. 30,300	Wickham, J. Scot Reg. No. 41,376
Edell, Robert T. Reg. No. 37,830	McKenzie, Denise L. Reg. No. 40,620	Reg. No. 28,650	Williams, Douglas J. Reg. No. 27,054
Epp Ryan, Sandra Reg. No. 26,896	Mueller, Douglas P. Reg. No. 36,233	Reg. No. 36,233	Wim, Jonelle Reg. No. 41,980
Farber, Michael B. Reg. No. 40,620	Nasiedlak, Tyler L. Reg. No. 40,620	Reg. No. 40,620	Wood, Gregory B. Reg. No. 28,133
Funk, Steven R. Reg. No. 40,620	Nelson, Albin J. Reg. No. 40,620	Reg. No. 40,620	Wood, William Reg. No. P-42,236
Glance, Robert J. Reg. No. 26,896	Parker, Sandra M. Reg. No. 40,620	Reg. No. 40,620	Xu, Min S. Reg. No. 39,536

I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/organization/who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct Merchant & Gould to the contrary.

Please direct all correspondence in this case to Merchant, Gould, Smith, Edell, Welter & Schmidt at the address indicated below (or if no address is specified, the first address):

- ☒ 3100 Norwest Center, 90 South Seventh Street; Minneapolis, MN 55402-4131 (Telephone No. (612) 332-5300)
- ☐ Independence Plaza, Suite 1400; 1050 17th St.; Denver, CO 80265-0100 (Telephone No. (303) 357-1670)
- ☐ Westwood Gateway II, Suite 400; 11150 Santa Monica Boulevard; Los Angeles, CA 90025-3395 (Telephone No. (310) 445-1140)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Insert FULL name(s)  
AND address(es) of  
actual inventor(s)

2	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
0	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
1	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
2	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
0	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
2	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
2	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
0	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
3	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
SIGNATURE OF INVENTOR 201		SIGNATURE OF INVENTOR 202		SIGNATURE OF INVENTOR 203
DATE		DATE		DATE

Each inventor must  
sign & date

Note: No legalization or  
other witness required

Revised 1/25/99

For Additional Inventors:

☐ Check box and attach sheet with same information, including date and signature.